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Rheumatoid arthritis is a common disease which seems to be interlinked with 
impaired fertility. How exactly this disease might affect fertility is largely unknown. 
This introduction will provide an overview of the possible interaction between 
rheumatoid arthritis and fertility. Before doing so we will provide some basic 
understanding of rheumatoid arthritis in general. Next, a description is given of 
ovarian function and its regulators. Furthermore, the available literature on fertility in 
rheumatoid arthritis will be summarized. The latter will be followed by a description 
of the design of the PARA study, which has been the fundament for the main part of 
this thesis. Finally, the objectives of this thesis will be described as well as its outline.
Rheumatoid arthritis
Rheumatoid arthritis (RA) is a chronic systemic inflammatory auto-immune disease. 
With a prevalence of 0.5 – 1.0 % of adults in Western countries, it is one of the most 
common auto-immune rheumatic diseases.1 Typically, RA occurs more often in 
females than in males.2,3 The incidence of RA increases with age.4 Over all ages, and 
especially in adults younger than 45 years, more women than men are affected.2 
Over time, RA can lead to permanent joint damage5, but extra-articular manifestations 
are also common.4 In patients with RA, mortality rates are increased, amongst 
others through an increased risk from cardiovascular, infectious, hematologic, 
gastrointestinal , and respiratory comorbidities and complications.6
Serology
Autoantibodies are often present in RA. The presence of rheumatoid factor (RF) and 
anti-citrullinated protein antibodies (ACPAs) can precede a clinical diagnosis of RA by 
years.7,8 RF was the fi rst known antibody associated with RA, and has been part of past 
and future classifi cation criteria for RA.5,9,10 ACPAs have been discovered more recently, 
and their presence is highly specifi c for the development of RA.10 Furthermore, ACPAs 
are more discriminative than RF in distinguishing RA from other arthritic diseases.11 
Moreover, ACPA positive patients appear to have a different form of RA than ACPA 
negative patients, with ACPA positive patients having a higher chance of radiological 
joint damage, more extra-articular manifestations, and a different response  to anti-
rheumatic therapy, often requiring a more  intensive treatment strategy.10
Diagnosis
For decades, patients were diagnosed with RA when the disease had already reached 
a destructive state and had caused permanent joint damage. For study purposes, 
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several sets of classification criteria have been developed over the years. Of these, 
the 1987 the American College of Rheumatology (ACR) criteria have been applied 
for many studies worldwide.9 The 1987 ACR criteria for classification of RA include: 
morning stiffness, the number of affected joints, the location of the affected joint 
areas, symmetry of arthritis, the presence of rheumatoid nodules, the presence of 
serum RF, and radiographic changes. When 4 out of 7 criteria are present for six or 
more weeks, a patient is considered having certain RA.9 
In 2010, a new set of classification criteria was developed to allow for early recognition 
of possible RA, and consequently for early start of anti-rheumatic treatment: the 
2010 ACR/European League Against Rheumatism (EULAR) classification criteria.5 
When applying these criteria, points are assigned to the number of large or small 
joints involved, the presence of low-positive or high-positive RF or ACPA, abnormal 
C-reactive protein (CRP) levels or erythrocyte sedimentation rate (ESR), and the 
duration of symptoms ≥6 weeks. When a patient has 6 or more points, a diagnosis of 
definite RA can be made.5
Disease activity score
To compare disease course between patient groups and monitor patients’ responses 
to anti-rheumatic therapy, RA disease activity can be measured using the Disease 
Activity Score (DAS) with a 44 joint count, or the modified DAS28 using a 28 joint 
count.12 Aside from the tender and swollen joint count, the DAS also includes the 
ESR or the serum CRP level, and optionally a visual analogue scale for global health 
(GH). By selecting the items included in the DAS, the score can be adjusted to specific 
situations, such as pregnancy. Overall changes in ESR and GH scores in pregnant 
women may influence the DAS. It has been shown, that the DAS28-CRP without GH 
component, is the least affected by pregnancy itself.13 The DAS28 ranges from 0 to 
10, indicating how active the RA is at that moment. Remission criteria have also been 
developed, with patients with a DAS28 below 2.6 being considered in remission.14 
Anti-rheumatic treatment
To prevent or limit long-term damage due to RA, the current EULAR guideline (2010) 
recommends the start of anti-rheumatic drugs as soon as a patient is diagnosed, or 
when a diagnosis of RA is suspected. The guideline describes a treat-to-target regimen 
with synthetic disease modifying anti-rheumatic drugs (DMARDs) as first step 
treatment after the diagnosis of RA.15 Anti-rheumatic therapy should aim at disease 
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remission or alternatively a state of low disease activity. Methotrexate (MTX), a folic 
acid antagonist, is the treatment of fi rst choice. Other synthetic DMARDs include 
sulfasalazine, leflunomide, and antimalarial drugs such as hydroxychloroquine. 
Combination therapy with several synthetic DMARDs has been proven to be more 
effective than monotherapy.16,17 Since in general DMARD therapy starts to be effective 
after 6 to 12 weeks, the fast-acting glucocorticoids can be added as a bridging therapy 
to the DMARDs for a short period of time to enhance the anti-rheumatic effect.15 
When therapy with synthetic DMARDs does not result in low disease activity or 
remission, biologic DMARDs such as tumor necrosis factor (TNF) inhibitors are 
the next treatment option.15 When a patient achieves persistent remission, anti-
rheumatic drugs can be tapered with caution, one by one, always aiming at sustained 
remission for each individual patient.18
Aside from synthetic or biologic DMARDs, RA patients often use non-steroidal 
antiinflammatory drugs to manage pain and stiffness. However, the use of NSAIDs 
does not prevent long term damage in RA.1 
Anti-rheumatic treatment during the preconception period
When a woman with RA wishes to conceive, the most common fi rst-step treatment, 
the folic acid antagonist MTX, is contra-indicated because of teratogenicity.19 Because 
of insuffi cient evidence of the safety of numerous other anti-rheumatic drugs, such 
as leflunomide, abatacept, rituximab, tocilizumab, ustekinumab and anakinra, 
expert advice has been to discontinue these agents.20,21 In a subgroup of patients, 
anti-rheumatic treatment is stopped completely during the preconception period or 
in early pregnancy.22 However, it is advised not to stop all anti-rheumatic treatment 
completely, because active disease in the mother can lead to a less favourable outcome 
of pregnancy. A higher disease activity during pregnancy has been associated with a 
lower birth weight, and an increased risk for delivery through caesarean section.23 
Recently, an EULAR task force on anti-rheumatic drugs before, during and after 
pregnancy has reported that active disease can be treated effectively with reasonable 
safety for the foetus or newborn during pregnancy and lactation.20
In daily practice, many rheumatologists have been reluctant of prescribing 
medication during pregnancy, due to possible teratogenicity or adverse effects during 
pregnancy.21 Therefore, over the last decade pregnant women with RA were mainly 
treated with steroids, sulfasalazine, and hydroxychloroquine, or did not receive any 
anti-rheumatic treatment despite active disease during the preconception period 
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and in pregnancy. Often, NSAIDs were added for pain management.21 A minority of 
pregnant RA patients received biologic DMARDs.22,24 Over the past years, more data on 
the use of the biologic DMARDs has become available. Since TNF inhibitors appear to 
be safe before and during pregnancy, at least until the end of the second trimester25-28, 
their use among women with RA trying to conceive is increasing nowadays.20
Ovarian function and ovarian ageing 
Female fertility decreases with increasing age. Generally, women above 30 years of age 
are considered to have gradually decreasing fertility over time, with an acceleration in 
declining fertility after the age of 37 years. On average female fertility is considered 
to come to an end around an age of 40 years.29 However, this varies considerably 
between women since there are women who lose their fertility as early as 30 years 
of age, or as late as 45 years of age. This decrease in fertility with increasing age is 
attributed to a decreasing ovarian function through the reduction in the number of 
ovarian primordial follicles over time and a concomitant decrease in oocyte quality.30,31 
In the female foetus, mitosis of germ cells results in approximately 7,000,000 oocytes 
in the developing ovaries.32 Once they have entered meiosis, the number of oocytes 
ceases to increase.32 During early folliculogenesis, when somatic cells surround the 
oocytes to form primordial follicles, the majority of germ cells are eliminated. As a 
result,  a number of 700,000 to 1,000,000 oocytes are present in the ovaries at birth.33,34 
During childhood, the number of oocytes further decreases, and at menarche, the 
primordial follicle pool consists of approximately 400,000 oocytes.33 
During the reproductive period, every menstrual cycle a number of around 800-1000 
primordial follicles will grow and leave the primordial pool. Rising and subsequent 
decreasing levels of follicle stimulating hormone (FSH) will cause one follicle to 
become dominant, which can be fertilized after ovulation. The other follicles that left 
the primordial follicle pool will become atretic and are lost.27 This cyclic recruitment 
and subsequent follicle atresia cause a continuous decline of the primordial follicle 
pool. (Figure 1) When the primordial follicle pool is nearly exhausted and only 
contains approximately 1,000 follicles, no more cyclic follicle growth occurs and 
anovulation sets in. As a definite hallmark a woman's menstrual periods will stop 
and hence menopause occurs33. On average, menopause is reached at an age of 50-51 
years, with a broad range spanning 20 years and ranging from 40-60 years.31 However, 
in populations not interfering with natural infertility the age at which the last child 
is born is on average around an age of 40-41 years. Hence, fertility and also fecundity 
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ends approximately 10 years before menopause occurs.31  It is therefore that the age at 
which fertility ends has a similar broad range as the occurrence of menopause. 
Figure 1 – Wallace-Kelsey model describing the nongrowing follicle populations (NGF) from conception to 
menopause, and the 95% confi dence intervals and 95% prediction limits for the model. The predicted average 
age at menopause with this model is 49.6 years (95%PI 38.7–60.0 years). (Duplicated with permission from the 
author, source: Wallace, PLoS One 2010.35
Anti-Müllerian hormone as a measure of ovarian function
The size of the ovarian follicle pool can be estimated by measuring serum levels of 
anti-Müllerian hormone (AMH). AMH is a member of the transforming growth factor 
β family, and is well known for its role in the regression of the Müllerian ducts in 
the male foetus.36 In women, AMH is specifi cally produced by the granulosa cells of 
the small growing ovarian follicles.33,37  AMH levels are fi rst detectable in the female 
foetus at 36 weeks of gestation, when ovarian primordial follicles start developing 
into primary follicles.38 AMH expression is highest in secondary, preantral and small 
antral follicles (≤4 mm), until it disappears in larger antral follicles (4-8 mm).37 
AMH has a function in the regulation of follicle recruitment. In AMH knock-out mice, 
there is an increased rate of follicle recruitment, which leads to premature depletion of 
the ovarian follicle pool and consequently anovulation.39 Furthermore, AMH affects the 
sensitivity of follicles to follicle stimulating hormone (FSH) from the pituitary gland. In 
the absence of AMH, the individual threshold of a follicle for FSH seems to be lower.39  
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In women, AMH levels are highest during early adulthood. After that, just like 
the number of ovarian follicles, AMH levels decline over age, until serum AMH is 
undetectable around menopause.18
Currently, serum AMH levels are the most reliable predictor for the age at which a 
woman will enter menopause.40  Where other hormonal markers for ovarian function, 
such as follicle stimulating hormone (FSH), might vary throughout the menstrual 
cycle,  serum AMH concentrations are fairly stable throughout the menstrual cycle 
phases.41 Over the years, a variety of AMH assays have been developed, but large 
comparison studies of the different assays are lacking.42,43 More recently ultra-
sensitive assays have been introduced, which are able to measure serum AMH levels 
below the previous limits of detection.44
In pregnant women, lower serum AMH levels have been reported, with the lowest levels 
measured during the third trimester of pregnancy.45-48 The effect of oral contraceptives 
use on AMH levels has been studied, but results are inconclusive, with several studies 
reporting no effect of hormonal contraceptives on serum AMH levels49-51, and others 
finding decreased AMH levels in users of hormonal contraceptives.52-54
Regarding fertility, AMH levels have been reported to add to the prediction of live birth 
in assisted reproductive technology cycles55-59, and low serum AMH levels have been 
reported to be associated with a reduced chance of natural conception60, although 
results are not very consistent.61
Subfertility
In the majority of the general population, a pregnancy is achieved within one year of 
actively trying to conceive. However, for 10 to 15 percent of the couples having regular 
unprotected intercourse aiming at achieving a pregnancy, this goal is not met within 
12 months and they are considered subfertile.62
Several factors can compromise a couple's fertility. In the male partner, subfertility is 
often caused by a reduced sperm count (oligospermia), or absence of spermatozoa 
in the ejaculate (azoospermia). Causes can be pretesticular, testicular, and post-
testicular. Pretesticular disorders are mainly endocrine disorders.63,64 Testicular 
disorders, also known as primary testicular dysfunction, include congenital and 
genetic disorders, gonadotoxins including certain medication, and damage resulting 
from infection or trauma. Posttesticular causes include ejaculatory dysfunction, such 
as retrograde ejaculation, and obstructions of the reproductive tract. 
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The main causes of subfertility in women are anovulation, tubal occlusion, and 
endometriosis.65-67 Anovulation can have a central cause (hypogonadotropic 
hypogonadism), or an ovarian cause (such as ovarian failure, or polycystic ovary 
syndrome). Tubal occlusion can be bilateral or unilateral. 
In up to 30% of subfertile couples, no obvious cause is detected and hence they are 
referred to as couples with unexplained subfertility.65-67 
Fertility in rheumatoid arthritis 
In the past sixty years, numerous solitary reports on reproduction in women with 
RA have been published. The two oldest reports both describe a smaller family size 
in women with RA68,69, which has been confi rmed over time by several studies70-74. 
Nulliparity is more common in women with RA compared to controls70,75 and a single 
study has related this to the presence of RF69. When looking at the time to pregnancy 
(TTP), women with RA had a longer TTP than controls for the fi rst pregnancy and 
similarly for consecutive pregnancies either after or before the onset of RA.70 Already 
before disease onset, a TTP longer than 12 months was found in 42% of RA patients.76 
In a group of pregnant RA patients, 25 percent spent more than 12 months before they 
conceived.77 Moreover, more women with RA received fertility treatments compared 
to healthy women without RA.78
It has been reported that one in fi ve women with RA consider their disease in their 
childbearing decisions. These women had signifi cantly fewer pregnancies and fewer 
children than women who did not consider RA in childbearing decisions.72
Miscarriages in RA
The aim of reproduction is a live born baby after an uneventful pregnancy. Miscarriage, 
being early pregnancy loss before 16 weeks of gestation, occurs in 10-20% of pregnant 
women, with a the miscarriage rate increasing with advancing maternal age.79 
Reports on miscarriages in RA patients are scant and have produced contradictory 
results. An increased miscarriage rate has been reported by several authors70,78,80, 
whereas other studies have found no increase in miscarriage rates in RA patients.69,81-83 
When RA patients are exposed to MTX after conception, which is often the case in 
unplanned pregnancies in this patient group, the incidence of miscarriages is 
increased.19




Compared to healthy control women, menopause occurs slightly earlier in women 
with RA.69,70 Even in women with postmenopausal onset of the disease, the mean age 
at menopause was significantly lower compared to matched controls.69 However, not 
all studies have confirmed the younger age at menopause.75
Studying reproduction in RA – the PARA cohort
This thesis focuses mainly on patients from the Pregnancy-induced Amelioration of 
Rheumatoid Arthritis (PARA) study. The PARA study aimed to study the changes in 
the disease course of RA during pregnancy and the postpartum period.22 The PARA 
cohort was a nationwide observational prospective cohort, for which eligible patients 
from the Netherlands were recruited by their attending rheumatologists from May 
2002 until November 2008. Patients were eligible when they had a diagnosis of RA 
according to the 1987 revised ACR criteria9 and were trying to conceive or were already 
pregnant. Patients had to have a good understanding of the Dutch language. During 
the study, patients received usual medical care from their attending rheumatologist. 
Teratogenic medications, such as MTX, had to be stopped at least 3 months before 
trying to conceive.
Members of the PARA research team visited the patients at their homes during the 
preconception period (if possible), once during each trimester of pregnancy, and 
at six, twelve and 26 weeks postpartum. At each visit, questionnaires on health, 
medication use, and obstetric information were filled out. Blood and urine samples 
were collected at each assessment, and the RA disease activity was measured using a 
standardized swollen and tender joint count for 28 joints, which was combined with 
the serum C-reactive protein (CRP) levels (DAS28-CRP).13 
During the years of observation within the PARA cohort, it appeared that many 
patients had problems achieving a pregnancy. It often took patients longer to conceive, 
and a considerable number of patients needed artificial reproductive treatments to 
achieve pregnancy.23 
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Objectives and outline of this thesis
This thesis aims to give an overview of fertility in women with RA, and to look further 
into the association of fertility with RA disease characteristics and the use of anti-
rheumatic drugs. Therefore, this thesis has the following objectives: 
(I) to study the time to pregnancy and the occurrence of subfertility in 
women with RA, and their associations with clinical aspects of RA, 
(II) to look into the occurrence of miscarriages and its association with 
RA disease characteristics, 
(III) to study the ovarian function in women with RA, and its role in the 
TTP in female RA patients trying to conceive, and  
(IV) to investigate the long-term decrease of ovarian function over time 
in women with RA.
The fi rst part of this thesis, chapters 2, 3 and 4, will focus on fertility and reproductive 
outcome in women with RA. Chapters 5, 6 and 7 will assess ovarian function in RA 
patients. Next, chapter 8 will reflect on the results, discussing how these impact 
our current understanding of fertility in RA, what their implications for clinical 
practice are, and giving suggestions for future research. Finally, chapters 9 and 10 will 
summarize the main fi ndings of the different studies in this thesis. 
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Objectives: Many female rheumatoid arthritis (RA) patients attempting to conceive 
have a time to pregnancy (TTP) of >12 months. During this period RA often cannot 
be treated optimally. We sought to identify clinical factors associated with prolonged 
TTP in female RA patients.
Methods: In a nationwide prospective cohort study on pregnancy in RA patients 
(PARA study), women were included preconceptionally or during first trimester. Cox 
regression analysis was used to study the association of disease characteristics and 
medication use with TTP.
Results: TTP exceeded 12 months in 42% of 245 patients. Longer TTP was related to 
age, nulliparity, disease activity (DAS28), and preconception use of non-steroidal anti-
inflammatory drugs (NSAIDs) and prednisone. These variables were independently 
associated with TTP, with HRs for occurrence of pregnancy of 0.96 (95% CI 0.92 to 
1.00) per year of age, 0.52 (0.38 to 0.70) for nulliparity, 0.81 (0.71 to 0.93) per point 
increase in DAS28, 0.66 (0.46 to 0.94) for NSAIDs and 0.61 (0.45 to 0.83) for prednisone 
use. The impact of prednisone use was dose dependent, with significantly longer 
TTP when daily dose was >7.5 mg. Smoking, disease duration, rheumatoid factor, 
anti-citrullinated protein antibodies, past methotrexate use, and preconception 
sulfasalazine use did not prolong TTP.
Conclusions: TTP in RA is longer if patients are older or nulliparous, have higher 
disease activity, use NSAIDs or use prednisone >7.5 mg daily. Preconception treatment 
strategies should aim at maximum suppression of disease activity, taking account of 
possible negative effects of NSAIDs use and higher prednisone doses. 
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Conceiving a child is a major life event and most adults try to have a child during their 
reproductive life span. In women with inflammatory rheumatic disease, however, it 
seems to be more diffi cult to achieve parenthood.1 
Rheumatoid arthritis (RA) is one of the most prominent inflammatory diseases 
affecting women of child-bearing age. Nearly one-third of female RA patients 
diagnosed before completion of child-bearing experience fertility problems.2 They 
have a prolonged time to pregnancy (TTP), the time between the start of actively 
trying to conceive and actually becoming pregnant.3 Pregnant RA patients are more 
likely to have had fertility treatment than pregnant controls.3,4 Women with RA 
have fewer children than women without RA,5-9 and more often fail to conceive at 
all.7 Hence fertility as well as fecundity seems to be compromised in women with 
RA.
Subfertility in RA has been studied only in retrospective studies or comparisons of 
registries.2,3,5-9 None of these studies have extensively examined the causes underlying 
the higher subfertility in RA, which may include disease activity, anti-rheumatic 
medication and immunological factors.  
To identify clinical factors associated with a higher rate of subfertility in women 
with RA, we studied the TTP in consecutive RA patients who participated in a large 
prospective cohort study in the Netherlands on Pregnancy-induced Amelioration of 
Rheumatoid Arthritis (the PARA study).10
METHODS
Patients
Patients were drawn from the PARA study, an observational nationwide prospective 
cohort study on pregnancy in RA.10 The study was approved by the Erasmus MC 
medical ethics review board. 
From May 2002 until August 2008, rheumatologists in the Netherlands recruited 
RA patients defi ned according to the 1987 revised criteria of the American College of 
Rheumatology (ACR).11 To be eligible for the PARA study, patients should be actively 
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trying to conceive, or already pregnant. Teratogenic drugs, such as methotrexate 
(MTX), should have been stopped for at least 3 months. 
Only patients included preconceptionally or during the first trimester of pregnancy 
were eligible for the current analysis. If a patient participated twice or more, only the 
first study episode was included.
Data collection
Patients were preferably visited before conception, during each trimester, and three 
times after delivery. Patients who did not conceive within 1 year after the first visit 
were visited again 1 year later. At each visit, patients filled out questionnaires, were 
interviewed by a research team member, and provided details on variables possibly 
influencing fertility such as age, parity and smoking habits. Disease activity was 
measured and serum samples were stored at -80°C. Using a structured questionnaire, 
the researcher recorded the use, frequencies and dosages of anti-rheumatic 
medication. At the first visit, the researcher recorded the date the patient first began 
actively trying to conceive.
Patients who were already pregnant during the first visit were asked when their last 
menstrual period had started. We calculated the TTP as the time elapsed between 
the first attempt to conceive and the first day of the last menstrual period before 
pregnancy. If the date of the last menstrual period was not known by the patient, this 
date was calculated by subtracting 280 days (40 weeks) from the due date based on 
sonographic examination during early pregnancy. In several cases the couple started 
to try for pregnancy after the start of the last menstrual period and succeeded within 
that first month. To avoid negative values for the TTP, we calculated a fictitious date for 
the pregnancy test for all patients by adding 28 days to the start of the last menstrual 
period. These dates were used only in the univariate survival analyses and the Cox 
regression analyses. 
Measurements
Disease activity scores were calculated using the 28-joint Disease Activity Score 
(DAS28) with three variables based on the C-reactive protein (CRP) level (mg/L).12 
We categorised the disease activity scores according to the recommendations of 
the European League against Rheumatism (EULAR): in remission (DAS28≤2.6), low 
disease activity (2.6<DAS28≤3.2), intermediate disease activity (3.2<DAS28≤5.1) and 
high disease activity (DAS28>5.1).13
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Rheumatoid factors (RF) were measured by commercial ELISA (HYCOR Biomedical, 
Garden Grove, California, USA) or by the EliA RF IgM method on the ImmunoCAP 250 
(Phadia, Uppsala, Sweden). For RF, the level above which only 5% of healthy controls 
were tested as positive was defi ned as positive. The presence of anti-citrullinated 
protein antibodies (ACPA) was tested by fluoroenzyme immunoassay using  EliA CCP 
on the ImmunoCAP 250. A level >10 U/mL was considered positive.14
Statistics
Values are given as mean±SD, number (percentage), or median (IQR). We calculated 
inter-group differences using the Student t test or Mann-Whitney U test for continuous 
variables and Fisher's exact test for categorical variables. Differences between 
different time points were calculated by a paired t test or the Wilcoxon signed-ranks 
test. 
Differences in TTP per categorised variable were studied using Kaplan-Meier 
curves. The signifi cance of differences between curves was tested using the log-rank 
test. A multivariable analysis was performed by Cox regression analysis including 
age, nulliparity, smoking, disease duration, RF, ACPA, DAS28, non-steroidal anti-
inflammatory drug (NSAID) use, prednisone use, sulfasalazine use and previous MTX 
use. If the patient had not become pregnant at the last time of contact, the TTP was 
considered censored at the date of the last visit or contact.
A two-sided p-value of <0.05 was considered signifi cant. The statistical package Stata/
SE V.12.0 for Windows (StataCorp LP, College Station, TX, USA) was used.
RESULTS
Patients
Of 475 patients recruited from May 2002 to August 2008, 369 were enrolled in the 
PARA study, and 245 of these were available for the present analyses (fi gure 1). There 
were no statistical differences in general characteristics between included and 
excluded subjects.
Study population details are shown in table 1. During the study period, 205 women 
(84%) conceived, 64 of whom (31%) had a TTP longer than 12 months. These 64 women 
together with the 40 women who did not become pregnant during follow-up,  formed 
the subfertile group in this cohort (subfertility 42%). In the women who got pregnant, the 
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median TTP was 0.50 year (IQR 0.19–1.28). Pregnancy resulted in a live born baby in 178 
women (87%), 26 women (13%) miscarried and there was one intra-uterine fetal death. 
Thirty-five pregnant women had had fertility treatment. These women did not differ 
significantly from the other subjects. No data on fertility assessments were available.
Since only a few patients used cyclo-oxigenase-2 (COX-2) inhibitors, traditional 
NSAIDs and COX-2 inhibitors were regarded as one group for analyses.
In 61 women (25%) who were not assessed preconceptionally, only the first trimester 
DAS28 was available. In women who had been visited both preconceptionally and 
during pregnancy (n=109), a paired t test showed no significant difference between the 
preconception DAS28 (3.57±1.1) and the first trimester DAS28 (3.56±1.2; p=0.93). The 
first trimester DAS28 in these 109 women did not differ from the first trimester DAS28 
in women who had not been assessed preconceptionally (3.53±1.1; p=0.86)., The first 
trimester DAS28 was used for further analyses if the preconception DAS28 was missing.
Figure 1 – Flow chart showing the number of patients in the Pregnancy-induced Amelioration of Rheumatoid 
Arthritis (PARA) study who were available for the current analysis. ACPA, anti-citrullinated peptide antibodies; 
ACR, American College of Rheumatology; DAS28, 28-joint Disease Activity Score; RF, rheumatoid factor.
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Table 1 – Descriptive statistics of the study population
Variable Value*
Age, years 31.3±3.9
Nulliparity, n (%) 143 (58%)
Smoking, n (%) 34 (14%)
Duration of RA, years 3.6 (1.3–8.4)
RF positive, n (%) 180 (73%)
ACPA positive, n (%) 161 (66%)
Erosions present, n (%) 122 (50%)
MTX in the past, n (%) 161 (66%)
Biologicals in the past†, n (%) 37 (15%)
Disease activity (DAS28) 3.7±1.2





Non-selective NSAIDs 48 (20%)
COX-2 inhibitors 12 (5%)
Biologicals† 10 (4%)
Otherǂ 20 (8%)
*Values are given as mean±SD, n (%) or median (25th–75th percentile).
†Biologicals: etanercept, adalimumab, infliximab, anakinra.
ǂOther medications including gold, azathioprine and leflunomide.
ACPA, anti-citrullinated peptide antibodies; COX-2, cyclo-oxygenase-2; DAS28, 28-joint Disease Activity 
Score; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs; RA, rheumatoid arthritis; RF, 
rheumatoid factor.
Overall, 67% of women in the high disease activity group (DAS28>5.1), 43% of women 
in the intermediate disease activity group (3.2<DAS28≤5.1), 37% of women in the low 
disease activity group (2.6<DAS28≤3.2) and 30% of women in remission (DAS28<2.6) 
were subfertile (fi gure 2A).
In the subfertile group, age and DAS28 were signifi cantly higher than in the fertile 
group (table 2). Subfertile patients were more frequently ACPA positive and used 
NSAIDs and prednisone more often.
The women who did not become pregnant at all (n=40) had a signifi cantly higher 
DAS28 (4.14±1.3) than those who became pregnant (3.61±1.1; p=0.008).
RF positivity was more common in women who did not conceive (90%) than in those 
who did (70%; p=0.01). ACPA was positive in 80% of women who did not conceive 
compared to 63% of women who did get pregnant (p=0.05).  Disease duration did not 
differ signifi cantly: it was 4.4 (1.7–7.8) years in non-pregnant women and 3.4 (1.2–8.5) 
years in women who did get pregnant (p=0.76). 
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Figure 2 – Survival curves showing the time to pregnancy (TTP) in rheumatoid arthritis (RA) patients with (A) 
various levels of disease activity and (B) different prednisone dosages. When the TTP exceeded 1 year, patients 
were considered subfertile. If women had not become pregnant at the last time of contact, the TTP was 
considered censored at the date of the last visit. (A) Patients with high disease activity (DAS28>5.1) had a longer 
TTP than patients in the other groups (3.2<DAS28≤5.1, p=0.03; 2.6<DAS28≤3.2, p=0.04; DAS28<2.6, p=<0.001). 
Patients with intermediate disease activity (3.2<DAS28≤5.1) had a longer TTP than patients with RA in remission 
(DAS<2.6; p=0.008), but TTP did not differ significantly from that in patients with low disease activity 
(2.6<DAS28≤3.2). The TTP in patients with low disease activity did not differ significantly from that in patients in 
remission. (B) Patients using high prednisone dosages had a longer TTP than patients using low dosages 
(p=0.04), and a longer TTP than patients using no prednisone (p=0.002). The TTP between the low-dose group 
and the group with no prednisone did not differ significantly. DAS28, 28-joint Disease Activity Score.
Cox regression
Cox regression analysis with multiple variables showed that older age, nulliparity, 
higher DAS28, preconception use of NSAIDs, and preconception use of prednisone 
were associated with a longer TTP (table 3). Smoking, time since RA diagnosis, RF 
positivity, ACPA positivity, past MTX use, and preconception sulfasalazine use were 
not significantly associated with TTP.
When analysis was restricted to pregnancies resulting in a live birth, the same factors 
were identified as significantly associated with TTP (data not shown).
Because DAS28 and prednisone use may show interaction, we introduced an 
interaction term (DAS28 x daily prednisone dosage) into our model. This showed no 
significant effect (HR 1.00, 95% CI 0.99 to 1.02; p=0.41).
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Age, years 31.9±4.3 30.8±3.5 0.029 †
Nulliparity, n (%) 67 (64) 76 (54) 0.116 ‡
Smoking,  n( %) 15 (14) 19 (13) 0.853 ‡
Duration of RA, years 3.7 (1.1-8.8) 3.4 (1.5-7.9) 0.589 ¶
RF positive, n (%) 83 (80) 97 (69) 0.058 ‡
ACPA positive, n (%) 76 (73) 85 (60) 0.042 ‡
Erosions present, n (%) 52 (50) 70 (50) 1.000 ‡ 
MTX in past, n (%) 67 (64) 94 (67) 0.786 ‡
Biologicals in past, n (%) 16 (15) 21 (15) 0.527 ‡ 
DAS28 4.01±1.16 3.47±1.10 <0.001 †
NSAIDs, n (%) 35 (34) 25 (18) 0.007 ‡
Prednisone, n (%) 46 (44) 35 (25) 0.002 ‡
Sulfasalazine, n (%) 35 (34) 44 (31) 0.782 ‡
Spontaneous abortion, n (%) 11 (11) 15 (11) 1.000 ‡
* Subfertility is defi ned as a time to pregnancy >12 months. Values are given as mean±SD, median (IQR) and 
no.(%).
† Student's t test.
‡ Fisher's exact test.
¶ Mann-Whitney U test. 
ACPA, anti-citrullinated peptide antibodies; DAS28, 28-joint Disease Activity Score; MTX, methotrexate; 
NSAIDs, non-steroidal anti-inflammatory drugs; RA, rheumatoid arthritis; RF, rheumatoid factor. 
Table 3 – Cox regression analysis for occurrence of pregnancy in female patients with rheumatoid arthritis 
Variable HR 95% CI p Value
Age (per year) 0.96 0.92 to 1.00 0.038
Nulliparity 0.52 0.38 to 0.70 <0.001
Smoking 0.89 0.57 to 1.37 0.585
Disease duration (per year) 1.00 0.98 to 1.03 0.685
RF positivity 0.84 0.57 to 1.23 0.369
ACPA positivity 0.79 0.55 to 1.14 0.212
DAS28 (per point) 0.81 0.71 to 0.93 0.002
NSAIDs 0.66 0.46 to 0.94 0.022
Prednisone 0.61 0.45 to 0.83 0.002
Sulfasalazine 0.83 0.62 to 1.13 0.234
Past use of MTX 1.35 0.99 to 1.84 0.059
ACPA, anti-citrullinated peptide antibodies; DAS28, 28-joint Disease Activity Score; MTX, methotrexate; 
NSAIDs, non-steroidal anti-inflammatory drugs; RF,rheumatoid factor. 




The effect of prednisone usage on subfertility was further assessed. Eighty-five patients 
used prednisone in dosages of 2.5–20 mg daily (median 7.5 mg). They were divided into 
two groups: a low-dose group (≤7.5 mg prednisone, n=44), and a high-dose group (>7.5 
mg prednisone daily, n=41). In the high-dose group, 66% of women were subfertile 
compared to 43% in the low-dose group and 36% in the women who did not use 
prednisone. Kaplan-Meier curves showed a significant longer TTP in prednisone users 
versus non-users (p=0.005), and in high-dose users versus low-dose users (p=0.045) 
(figure 2B). In the Cox regression with the complete variable list, a dummy variable was 
introduced to distinguish between low-dose prednisone and high-dose prednisone. The 
HR for low-dose use was not significant (0.83, 95% CI 0.57 to 1.21; p=0.33), but use of 
high-dose prednisone significantly extended the TTP, with an HR of 0.50 (0.33 to 0.76; 
p=0.001). The significance of other variables in the analysis did not change.
A subgroup analysis on patients with DAS28 <3.2 still showed a significant association 
between prednisone use and a longer TTP (HR 0.21, 95% CI 0.10 to 0.45; p<0.001).  
DAS28 after 1 year
A subgroup of women who did not conceive within 12 months after the first visit, were 
revisited after one year. In the 17 patients who were still actively trying to conceive, the 
DAS28 for this visit did not differ from the DAS28 1 year earlier (3.96±1.6 vs 3.91±1.8; 
p=0.85).
DISCUSSION
In this prospective cohort of female RA patients, we showed that a prolonged TTP in 
RA is related to older age, nulliparity, higher disease activity, and preconception use of 
NSAIDs and prednisone (>7.5 mg daily).
Forty-two percent of the patients had a TTP exceeding 12 months. This is much higher 
than the reported subfertility of 9-20% in the general population with a pregnancy 
wish in Western countries.15,16 The median TTP of 6 months in pregnant RA women 
in our study is significantly longer than in the general Western European population, 
where 50% of women have a TTP of 3 months and approximately 70% conceive within 
6 months after starting unprotected intercourse.16 
The fertility rates in this study are similar to those shown by other studies in female 
RA populations of reproductive age. The proportion of 42% of subfertile women in 
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our study is consistent with a recent study that reported subfertility in 36% of women 
with RA diagnosed before family completion.2  A Danish birth registry study found a 
TTP exceeding 12 months in 25% of pregnant RA women.3 Since they did not include 
miscarriages or women who failed to conceive at all, these data are compatible with 
our study. 
We identifi ed various risk factors for a longer TTP in women with RA, including older 
age and nulliparity, which were already known to prolong the TTP. As in the general 
population, higher age negatively affects fertility.17 The mean age in our patient group 
was 31.3±3.9 years, which is slightly older than the mean maternal age at child birth in 
the Netherlands (31.0 years in 2000–2010).18 Therefore, we cannot explain the higher 
subfertility in this patient group by age alone. 
Concerning nulliparity, it has been shown that a previous pregnancy increases the 
chance of a subsequent pregnancy, at least in subfertile couples.19 In our study, 58% 
of patients were nulliparous compared to 47% in the general Dutch population.4 
Having a chronic disease may influence the time at which a woman starts having a 
family, or the choice to have fewer children, thereby explaining the higher number 
of nulliparous patients.20 It seems unlikely that the higher number of nulliparous 
patients would reflect a selection bias, with relatively more subfertile women 
enrolling in our study, since the subfertility rate in this study is comparable with that 
reported in the literature.2,3 Furthermore, it is not expected that this influenced the 
proper identifi cation of RA-associated risk factors for a prolonged TTP in this study. 
RA related factors that were associated with TTP in our cohort were DAS28, and 
preconception use of NSAIDs and prednisone >7.5 mg. To our knowledge, RA disease 
activity has not previously been related to reduced fertility, probably because of the 
retrospective design of previous studies. In inflammatory bowel disease, disease 
activity has been related to subfertility, but this is mainly attributed to tubal and 
ovarian dysfunction due to local inflammation or as a result of previous surgery.21 
The impact of high RA disease activity on fertility could be mediated via inflammatory 
mediators, since many cytokines, chemokines and growth factors play an important 
role in the preimplantation blastocyst-endometrial interactions.22 We have previously 
shown that high IL-6 serum levels are associated with lower birth weight in children 
born to women with RA.23 
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Since DAS28 did not increase during a 1-year follow-up in the preconception period, 
it is not likely that increasing disease activity over time explains an even longer TTP in 
these women.
The second factor is the use of NSAIDs. NSAIDs may interfere with ovulation, 
implantation and placentation through inhibition of prostaglandin synthesis.10,24,25 
Selective COX-2 inhibitors seem to inhibit ovulation more potently than traditional 
non-selective NSAIDs. However, this finding is only based upon case reports or small 
case series.24 
Finally, the use of prednisone prolongs the TTP. Although prednisone has been 
considered not to have any effect on fertility when used for the treatment of chronic 
inflammatory diseases,26,27 our results show that in daily dosages >7.5 mg it does 
indeed significantly lengthen the TTP. A possible explanation for this may be the 
transient suppression of the hypothalamic-pituitary-ovarian axis by glucocorticoids. 
Glucocorticoids in therapeutic dosages have been shown to decrease luteinising 
hormone pulse frequency from the pituitary gland.28,29 Another possibility is a direct 
effect of prednisone on ovarian function or on the endometrium.30-32 
Use of MTX in the past did not have a negative effect on the TTP. This is in contrast to 
animal studies, where MTX has been shown to cause a reduction in the number of 
primordial follicles (i.e. ovarian reserve) and a subsequent loss of ovarian function.33 
We have previously shown that short term MTX use in early RA does not affect ovarian 
reserve.34 As the women in the current study had been using MTX for several years, 
our results suggest that long-term use of MTX also does not have a negative effect on 
ovarian function and fertility.
Even in the era of biologicals, our results are still relevant due to safety concerns 
regarding biologicals during pregnancy, and because not all women have access to 
them. Therefore, prednisone and NSAIDs are still important anti-rheumatic drugs 
during pregnancy and the preconception period.
It has been reported that women with inflammatory joint disease are more often 
nulliparous when diagnosed in early adulthood than when diagnosed in childhood 
or at a later age.9 However, introducing age at diagnosis into our analysis has no 
significant effect on TTP (data not shown). 
A reduced frequency of intercourse may also play a role in explaining the observed 
fertility problems. If a patient has chronic pain (eg, in the hip or knee joints), intercourse 
frequency is expected to be lower, thereby diminishing the chance of conception in a 
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given month.  This was not assessed in our study, but after adjustment for DAS28, 
which reflects a patient's pain, other variables are still signifi cant.  
Body mass index (BMI) is also known to affect fertility. Overweight and underweight 
women both have a higher chance of ovulation disorders.35 Overweight women with 
regular menses also have an increased risk of subfertility.36 The association of RA with 
BMI is less clear.37,38 BMI was not recorded for the women included in the PARA study, 
but the median BMI for women 18-42 years in a representative Dutch RA cohort was 
24.2 (21.9-28.3).34 
Based upon our results, it should be recommended that RA patients trying to conceive 
should strive for low disease activity, thereby avoiding NSAIDs and daily dosages of 
prednisone exceeding 7.5 mg. The treatment of some women in our cohort, reflecting 
common care for women with RA during the preconception period,  does not seem 
to have been optimal as two-thirds of patients had a DAS28>3.2. While nearly a 
third of these women used no medication, over a third received monotherapy with 
sulfasalazine or prednisone. Combination therapy of sulfasalazine, prednisone and 
hydroxychloroquine in these patients may have resulted in lower disease activity.
Suppression of disease activity in RA women who wish to conceive is also important 
for the outcome of pregnancy. Higher DAS28 is associated with lower birth weight 
and rapid postnatal catch-up growth, which are both related to worse cardiovascular 
and metabolic profi les in adults.4,39 Use of prednisone during pregnancy is associated 
with lower birth weight due to delivery at lower gestational age and with higher 
cortisol levels in the offspring.4,40 Furthermore, women with high DAS28 more often 
undergo caesarean section.4
As the proportion subfertile women is much larger in the RA population than in the 
general population,15 patients likely to have a longer TTP might be helped by early 
consultation with a gynaecologist on options for reproductive treatment. If the TTP 
can be limited in these patients, this may prevent extended suboptimal treatment 
and consequently functional disability and progression of joint damage.
The results of our study also have implications for patients with conditions other than 
RA. When patients wish to conceive and are using high daily dosages of prednisone, 
or NSAIDs on a regular basis, their treatment should be critically evaluated. Similarly 
in patients with other inflammatory auto-immune diseases, disease activity may 
impair fertility and should be suppressed whenever possible.
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Objective: Subfertility is frequently encountered amongst female rheumatoid 
arthritis (RA) patients and has been associated with disease activity and anti-
rheumatic drugs. However, little is known about the results of the fertility work-up in 
these women. Our aim was to study the outcome of fertility assessments in subfertile 
women with RA.
Methods: A cross-sectional study was performed in a nationwide cohort of female 
RA patients who were pregnant or were trying to conceive between 2002 and 2010 
(PARA study). Patients who had given consent for future contact (n=260) received 
a questionnaire on reproductive history, fertility work-up and fertility treatments. 
Medical files were obtained from attending gynaecologists.
Results: A completed questionnaire was returned by 178 women (68%), of whom 
96% had ended their efforts to conceive. Eighty-two subjects (46%) had at least 
one subfertile episode, and for 61 women a diagnosis for subfertility was available. 
Unexplained subfertility (48%) and anovulation (28%) were the most common 
gynaecological diagnoses, and both occurred more often in RA patients than reported 
in the general population. Women with unexplained subfertility more often used 
NSAIDs during the periconceptional period. Seventeen percent of all pregnancies 
were conceived after fertility treatments. Fertility treatments had equal or higher 
pregnancy rates in RA compared to other subfertile populations. 
Conclusion: Unexplained subfertility is more often diagnosed in subfertile female RA 
patients than in the general population, and is related to periconceptional NSAIDs 
use. Despite the higher incidence of subfertility in women with RA, the outcome of 
fertility treatments in these women appears favourable.
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Fertility is compromised in women with rheumatoid arthritis (RA). They often have 
fewer children than they intended to have and they are more often nulliparous.1,2 
In 36-42% of female RA patients, diagnosed before family completion, the time to 
pregnancy (TTP) exceeds twelve months,1,3 whereas in the general population, this is 
only the case in 10-17% of couples.4-6 Since in most women with RA anti-rheumatic 
treatment has to be adjusted before they start trying to conceive, a longer TTP can 
result in a prolonged period with less adequately controlled disease and consequently 
an increased risk for permanent damage to the joints. Hence, understanding the 
underlying mechanisms of subfertility in RA, and treatment of these mechanisms 
whenever possible, would be an important step forward in the care for these patients.
Fertility in a couple might be compromised by many different factors, in the male 
as well as in the female partner. Male factors for subfertility include disorders in 
spermatogenesis or obstructions – causing oligospermia or azoospermia – and 
ejaculatory dysfunction. Female causes include anovulation, unilateral or bilateral 
tubal occlusion, and endometriosis. In 8-28% of subfertile couples no specifi c cause 
is found during fertility assessments. They are generally referred to as couples with 
unexplained subfertility.5,7
In most studies on fertility in RA, gynaecological data are missing. It has been reported 
that pregnant women with RA more often had a fertility treatment than pregnant 
controls.8 However, little is known on the outcome of fertility assessments, and details 
on subfertility diagnoses have not been reported. 
To study the outcome of fertility assessments in women with RA who suffer from 
subfertility, we performed a cross-sectional study in female RA patients from the 
Pregnancy-induced Amelioration of RA (PARA) cohort.
PATIENTS AND METHODS
Patients
Patients from the PARA study were invited to participate. The PARA study was a 
nationwide prospective observational cohort in the Netherlands (2002-2010) which 
included women with RA (1987 revised ACR criteria9) who were trying to conceive 
or were in their fi rst trimester of pregnancy.  PARA participants had to have a good 
understanding of the Dutch language and were allowed to participate more than 
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once. Both the PARA study and this follow-up study were approved by the Erasmus 
MC medical ethical review board. Of the 297 patients in the PARA cohort, 290 women 
gave permission to be contacted for future research. For 30 of them no current address 
was known.
For comparison of the occurrence of different subfertility diagnoses in women with 
RA to the general population, the incidence of these diagnoses in two reference 
populations with subfertility are reported.5,7
Data collection
Eligible patients received a printed questionnaire accompanied by a postage paid 
return envelope. Questionnaires included questions on their reproductive history, 
TTP in months and mode of conception for each pregnancy, visits to a gynaecologist, 
fertility assessments and fertility treatments. 
When patients consented, data on fertility assessments were collected from the 
previously attended gynaecologists. The received files and letters were checked 
for menstrual cycle length, cycle irregularities and their classification (according to 
the World Health Organization (WHO) classification10), measurements of follicle 
stimulating hormone, oestrogens and progesterone, presence of ovulation, history 
of pelvic inflammatory disease, tests for tubal function (hysterosalpingography, 
laparoscopy), presence of endometriosis, abdominal adhesions and sperm analysis. 
The diagnosis was recorded. Furthermore, data on performed fertility treatments 
and their results were collected. When not all required data could be extracted from 
the received information, another letter was sent to the gynaecologist requesting 
explicitly for the missing items. In cases where the fertility work-up was not reported 
in full detail in the information received, we registered the diagnostic conclusion 
reported by the gynaecologist, assuming the work-up was performed according to 
the general consensus, as described in the national guideline by the Dutch Society for 
Obstetrics and Gynaecology (NVOG).11 These guideline describes that in all couples 
consulting a gynaecologist for subfertility  a fertility work-up includes at least: 
excluding anovulation by measuring a mid-luteal serum progesterone, assessing 
the male's fertility by performing a sperm analysis, and establishing Fallopian 
tube patency either by doing a Chlamydia antibody screening or by performing a 
laparoscopy or a hysterosalpingogram.
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According to the national guideline (www.nvog.nl) unexplained subfertility was 
recorded when fertility assessments did not show any plausible explanation for the 
delay in the occurrence of a pregnancy.12
RA disease characteristics were drawn from the PARA study database,13 including date 
of diagnosis, presence of rheumatoid factor (RF) or anti-citrullinated protein antibodies 
(ACPA), and disease activity scores.13 Disease activity was scored using tender and 
swollen joint counts in 28 joints, and serum C-reactive protein levels (DAS28-CRP-
3).14When available the preconceptional DAS28 of the designated PARA episode was 
used, otherwise the fi rst trimester DAS28 of the same episode was used.3 
Statistical analysis
To study potential selection bias, participants and non-participants were compared 
on obstetric history and disease characteristics as recorded during the last PARA 
episode that a subject had participated. Intergroup differences were calculated using 
the Student's t-test and Mann-Whitney U-test for continuous outcome and the Chi-
squared test or Fisher's exact test for categorical outcome. Numbers of pregnancies, 
children and miscarriages were compared using a Mann-Whitney U-test. 
The association of subfertility diagnoses with RA disease characteristics were studied 
using the Chi-squared test, Fisher's exact test or Student's t-test. Disease activity scores 
and periconceptional use of NSAIDs and prednisone from the fi rst subfertile episode 
in the PARA study were used. A two-sided p-value <0.05 was considered signifi cant. 
Software used was IBM SPSS statistics version 21 and STATA/SE 14.1 (StataCorp). 
RESULTS
Participants
Of the 260 questionnaires sent, 178 (68%) were completed and returned (fi gure  1). 
Participants and non-participants were compared (table 1). Signifi cantly more 
non-participants had not achieved a pregnancy during their most recent PARA 
study episode (37%) compared to participants (17%) (p=0.001). More often, non-
participants were nulliparous at the end of their participation in the PARA study (24% 
versus 9%, p=0.002). There were more smokers among non-participants (22%) than 
in participants (6.7%) (p=0.001). Participants and non-participants did not differ 
signifi cantly regarding age, education level, number of children they had already had, 
disease characteristics, or percentage of miscarriages or pregnancy complications.
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Figure 1. Flowchart of the study population and inclusion of study participants. 
Reproductive history
Of the participants, 170 women (96%) had ended their efforts to establish a 
pregnancy. Reasons to stop trying to conceive were (multiple answers per subject 
possible): a complete family (72%), advanced age (20%), increase of RA complaints 
or the need for anti-rheumatic drugs incompatible with pregnancy (together 19%) or 
other health problems that complicated conception or taking care of a child (3%). In 9 
women (5%) there were no more fertility treatments available or their gynaecologist 
advised against a new pregnancy. In 3% the mental burden of the wish to conceive was 
a reason to end their attempts at pregnancy, and in 1% relational problems played a 
role. In total 28% ended their efforts before they felt their family was complete. Fifty-
nine women (33%) put their efforts to conceive on hold for one or more intervals, and 
in 32% of them this was due to RA complaints or the need for anti-rheumatic drugs 
incompatible with pregnancy.
The participants had a total of 412 pregnancies, with a median of 2 pregnancies 
(IQR 2-3, mean 2.3 ± 1.0) per woman. Of all reported pregnancies, 354 pregnancies 
(86%) were conceived after diagnosis of RA. Thirty-three percent of the women had 
one or more miscarriages (median 0, IQR 0-1, mean 0.42 ± 0.69). The total number 
of miscarriages was 75. There were 334 live born children in the study population 
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(median 2 (IQR 1-2, mean 1.9±0.78) per woman), with a maximum of 4 children per 
woman. Nine women (5%) remained nulliparous, of whom six (3% of participants) 
had never been pregnant and three women (2%) had only had pregnancies resulting 
in a miscarriage.




Current age (years) 40.5 ± 4.2 40.6 ± 4.3 0.834 ƚ
missing 1 (0.6%) -
Education level 0.51§¥
Low 11 (6.2%) 5 (6.1%)
Intermediate 74 (42%) 18 (22%)
High 93 (52%) 28 (34%)
missing - 31 (38%)
At start of last PARA episode
Age during PARA (years) 32.4 ± 4.0 32.5 ± 4.0 0.905 ƚ
missing 2 (1.1%) -
Number of previous children 1 (0–1) 0 (0–1) 0.55β
mean 0.61 ± 0.63 0.59 ± 0.72
missing - 1 (1.2%)
Smokers 12 (6.7%) 18 (22%) <0.001ǂ
missing 2 (1.1%) 2 (2.4%)
Duration of RA in years 15.0 ± 6.6 13.7 ± 5.9 0.135 ƚ
RF positivity ** 129 (72%) 59 (72%) 0.826ǂ
missing 4 (2.2%) 1 (1.2%)
ACPA positivity ** 114 (64%) 55 (67%) 0.584ǂ
missing 1 (0.6%) 1 (1.2%)
Periconceptional DAS28 ** 3.7 ± 1.2 3.5 ± 1.3 0.394 ƚ
missing 17 (9.6%) 4 (4.8%)
Obstetric outcome of last PARA participation
Achieved pregnancy 147 (83%) 52 (63%) 0.001 ǂ
    Life birth* 143 (97%) 50 (96%) 0.653 ¥
    Miscarriages* 4 (2.7%) 1 (1.9%) 1.000 ¥
    Maternal complications* 39 (27%) 12 (23%) 0.715 ¥
    Neonatal complications* 24 (16%) 7 (13%) 0.824 ǂ
Nulliparous at end PARA study 16 (9.0%) 20 (24%) 0.002 ¥
missing 1 (0.6%) 2 (2.4%)
Values are given as mean ± S.D., number(%), and median (interquartile range). * As a percentage of achieved 
pregnancies during last PARA participation. ** At the start of last PARA participation. P-values were calculated 
using ƚ  unpaired T-test, ǂ Chi2 test, ¥ Fisher's Exact test (§ on non-missing data), and β Mann-Whitney U test. 
PARA=pregnancy-induced amelioration of rheumatoid arthritis; RA= rheumatoid arthritis; RF = rheumatoid 
factor; ACPA = anti-citrullinated protein antibodies; DAS28 = disease activity score with a 28 joint count.




Eighty-two women (46%, 95%CI 39–53%)) were considered subfertile because they 
met at least one of the following criteria: a TTP exceeding 12 months during at least 
one attempt to establish a pregnancy (n=66), the use of fertility treatments to get 
pregnant (n=41), or never having achieved a pregnancy (n=6). Sixty-six women (37%) 
had a primary subfertility, and 16 women (9%) suffered from secondary subfertility. 
The mean age during the first subfertile episode was 29.4 ± 3.9 years.
Subfertile women established significantly less pregnancies (2 (IQR 1-2, mean 2.1 
± 1.1) vs 2 (IQR 1-3, mean 2.5 ± 1.0), p=0.004) and had less children (2 (IQR 1-2, mean 1.6 
± 0.9) vs 2 (IQR 1-2, mean 2.1 ± 0.6), p<0.001) than fertile women with RA. The number 
of miscarriages per woman in both groups was not significantly different (p=0.33).
The total number of pregnancies in the subfertile women was 168, resulting in 132 life 
born children. Of these pregnancies, 52 (31%) were conceived spontaneously within 
12 months, 48 spontaneously conceived pregnancies (29%) had a TTP >12 months, 
and 68 pregnancies (40% i.e. 17% of all pregnancies) were conceived with the help of 
fertility treatments (figure 2).
Figure 2 - Overview of study participants, pregnancies and subfertility.  TTP = time to pregnancy; FT = fertility 
treatment
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Eight subfertile women (10%) had never visited a gynaecologist. Of the other 74 
subfertile women, 65 women (88%) gave permission to collect data from their 
gynaecologist. For 64 women data was obtained, of whom 61 women received a 
diagnosis for subfertility. The other 3 women became pregnant spontaneously before 
the fertility work-up was completed. The 61 women with a diagnosis were compared 
to the 21 subfertile women without available diagnosis, showing no signifi cant 
differences regarding age, reproductive history, or disease characteristics. More 
women without available gynaecological fi les had ever used methotrexate (81% 
versus 54%, p=0.030).
In the 61 women for whom a diagnosis for subfertility was available, subfertility was 
most often caused by unexplained subfertility (48% of known diagnoses), anovulation 
(28%) and semen abnormalities (16%) (table 2). In 2 women (3%) anovulation was due 
to primary ovarian insuffi ciency (POI). In 5% of the couples there was both a female 
and a male cause for subfertility. For 8 of the 61 couples the gynaecologist did not 
report the result of a sperm analysis. Diagnoses in these women were: unexplained 
(n=2), vaginismus (n=1), anovulation (n=4) and endometriosis (n=1). For the 10 women 
for whom no gynaecology fi le was available, the self-reported diagnoses were: 
unexplained subfertility (n=4), tubal factor (n=2), anovulation (n=3, n=1 due to POI), 
and endometriosis (n=1) (table 2).
Of the women diagnosed by a gynaecologist (n=61), 56 (92%) had a subfertile episode 
in the PARA study, of whom 27 had unexplained subfertility and 14 had anovulation. 
When comparing women with unexplained subfertility to other subfertile RA 
patients, there was a signifi cant difference in periconceptional NSAIDs use (48% 
vs 17%, p=0.013), which was also signifi cant when self-reported diagnoses were 
included (NSAIDs use 45% vs 22%, p=0.046). None of the other associations, amongst 
which were disease activity and periconceptional prednisone use, were signifi cant. 
Women with anovulation showed no statistically signifi cant differences compared to 
ovulatory subfertile women. 
Fertility treatments
The most frequently performed fertility treatments are summarized in table 
3. Treatments were performed in 59 subfertile women (72%), which is 80% of 
the women who visited a gynaecologist for subfertility. In 41 women (50% of all 
subfertile women), fertility treatments resulted in at least one pregnancy, and in 28 
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of these women all conceptions were with the help of fertility treatments. Thirteen 
of the 20 women (65%) who started an in vitro fertilization (IVF) treatment had 
had intra-uterine inseminations (IUIs) before. Treatments not reported in the table 
are intravaginal insemination (1 subject), oocyte donation (1 subject), and sperm 
donation (2 subjects).











N % of subjects N % of subjects % of subjects
Unexplained subfertility‡ 29 48% 33 46% 31% 12%
Anovulation*/** 17 28% 20 28% 21% 32%
Male factor* 10 16% 10 14% 26% 58%
Endometriosis 4 6.6% 5 7.0% 6% 4%
Tubal occlusion* 2 3.3% 4 5.6% 14% 26%
Vaginismus 2 3.3% 2 2.8% NA NA
* In 2 couples there was both anovulation and a male factor. In 1 couple there was both tubal occlusion and a male factor. 
** In 2 women anovulation was due to premature ovarian insufficiency (POI).
‡ Unexplained subfertility includes a diagnosis of cervical hostility
Table 3 – Fertility treatment results in female rheumatoid arthritis patients from the PARA study
Treatment Subjects N of treatments Resulted in pregnancy Pregnancy rate






per cycle per woman§
IUI** 36 178 (1-11) 3 12 19 11% 33%
OI 17 77 (1-12) 3 10 15 19% 59%
IVF 20 42 (1-4) 1 10 17 40% 50%
ICSI 8 25 (1-6) - 8 15 60% 100%
IUI = intra-uterine insemination. OI=ovulation induction (with either clomiphene citrate or follicle stimulating hormone 
injections).  IVF = in vitro fertilization. ICSI = intra-cytoplasmic sperm injection.
* 18 women had 2 types of treatments, 4 women underwent 3 different types of treatment.
† 1 women achieved a first pregnancy after IUI, and a second pregnancy after IVF. 1 woman conceived twice after IUI 
combined with OI.
§ Percentage women with at least one pregnancy of total number of women who started treatment.
** In 10 women IUI was combined with mild ovarian hyperstimulation (MOH). 9 pregnancies were after IUI with MOH.
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This study aimed to explore the outcome of fertility assessments in those RA 
patients with subfertility. We found that subfertility in women with RA was most 
often unexplained or caused by anovulation. Moreover, the majority of subfertile RA 
patients received fertility treatments, and a considerable number of all pregnancies 
were conceived after women had been treated for subfertility. 
In comparison to the general population, female RA patients appear to be more often 
diagnosed with unexplained subfertility,5,7,15,16 whereas the percentage of subfertile 
women with anovulation was equal or slightly increased compared to percentages 
found in the general population.5,7,15,16 The incidence of primary ovarian insuffi ciency 
(POI) appears to be higher than in the general population.17
The high percentage of RA patients diagnosed by the gynaecologist with unexplained 
subfertility may imply that fertility in female RA patients is influenced by disease 
related factors. There was a signifi cant association of periconceptional NSAIDs 
use with unexplained subfertility. This is in concordance with a previous study 
within the PARA cohort where we have shown that a longer TTP was associated 
with the periconceptional use of NSAIDs, also when corrected for disease activity 
scores.3 In this previous study, a longer TTP was also associated with an increase in 
periconceptional disease activity and the periconceptional use of prednisone.3 The 
current results did neither show signifi cant differences in disease activity nor in 
periconceptional prednisone use between unexplained subfertile women and other 
subfertile RA women. However, since the current study was not designed to look into 
these associations, the numbers of patients in these comparisons were relatively 
small, and the timing of the study visit was not concurrent with the timing of the 
fertility work-up, these results do not exclude disease activity or prednisone use as a 
cause for subfertility in RA. 
Looking further into the association of NSAIDs with subfertility, NSAIDs have not 
been reported to compromise embryo-implantation in IVF treatments,18 but there 
have been reports on NSAIDs interrupting the ovulatory process, possibly leading 
to the so-called luteinized unruptured follicle (LUF) syndrome.19-22 In LUF syndrome, 
ovulation is inhibited without changes in menstrual cycle length and cycle regularity 
and therefore patients with LUF would probably be classifi ed as ovulatory during their 
fertility work-up. However, among gynaecologists the existence of LUF syndrome is 
controversial, and criteria for the existence of LUF syndrome include a laparoscopic 
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evaluation, with a strict timing, which is lacking in most studies on LUF syndrome.23 
Another explanation of the relation of NSAIDs use with unexplained subfertility 
may be the effect of pain on sexual intercourse. The use of NSAIDs may indicate that 
these women experience more pain and therefore they might have less exposure due 
to a decreased frequency of intercourse. Indeed, sexual intercourse in RA patients is 
more often limited by pain or fatigue,24 but studies specifically addressing intercourse 
frequency in RA patients who try to conceive have not been performed. Furthermore, 
in daily practice RA patients who are trying to achieve a pregnancy are often very 
motivated to have regular peri-ovulatory intercourse. However, disease activity was 
higher in patients who used NSAIDs versus non-users, suggesting that NSAIDs were 
taken for pain control. All patients using NSAIDs reported that this was because of RA. 
No patient reported the use of NSAIDs for other conditions.
The percentage of subfertile subjects who received fertility treatments was almost 
fifty percent higher than in the general population.4 Furthermore, the proportion of 
pregnancies that were conceived with the help of fertility treatments is  conform earlier 
findings in the PARA study,25 and is also in line with a Danish National Birth Cohort 
study reporting that more pregnant RA patients compared to pregnant controls 
had received a fertility treatment.8 The pregnancy rates per treatment cycle and per 
woman who started treatment were comparable to other subfertile populations as 
far as intrauterine insemination (IUI) and ovulation induction (OI) were concerned.26 
On the contrary, the pregnancy rates of IVF and IVF/ICSI treatments were both higher 
in RA women.27 Therefore, embryo implantation does not seem to be compromised 
in RA patients. An explanation for the higher pregnancy rate after IVF or ICSI 
might be explained by an early start of fertility treatment relative to their previous 
underexposure to preovulatory sexual intercourse. On the other hand, selection bias 
may have occurred when women who did not get pregnant after fertility treatments 
were mainly in the non-participants group. However, since data on the results of 
fertility treatments in these women were scarcely available, this remains unclear.
One in five women had stopped trying to conceive because of active disease or anti-
rheumatic drugs. In the PARA study, more than one third of the women did not use 
any anti-rheumatic drugs during the periconceptional period, and less than 5% of 
the women used biologicals preconceptionally, whereas the disease activity was 
intermediate or high in the majority of patients.3  Over the last decade, tumor necrosis 
factor inhibitors have been used increasingly in the periconceptional treatment 
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of women with RA, and appear to be safe.28 Since active disease is associated with 
a longer TTP,3 subfertile RA patients may benefi t from the preconceptional use of 
these biologicals, and fewer women would need to end their efforts to build a family 
because of active disease.
With a higher pregnancy rate and less nulliparity than non-participants, the 
participants in this study seemed to be a more fertile selection of the PARA cohort. 
Therefore our current results may very well be an underestimation of the real 
incidence of the total subfertility and their impact on childbearing in the total female 
RA population. Since the incidence of subfertility in the PARA cohort was consistent 
with other recent studies in female RA patients of reproductive age,3 it is not likely that 
selection on subfertility in the recruitment for the original PARA cohort introduced 
bias in the current study and affected our current results. 
An explanation for the lower pregnancy rate and higher nulliparity among the non-
participants may be that they were less desirous of achieving a pregnancy than the 
participants. However, this was not the case. No differences were found between 
participants and non-participants in the number of children already present before 
the fi nal PARA participation. Moreover, within the non-participants who did not 
achieve a pregnancy during the last PARA episode more women underwent fertility 
treatments than the non-pregnant participants, although this difference was non-
signifi cant (data not shown). Therefore, the motivation to achieve a pregnancy 
appeared not to be diminished in the non-participants.
On the other hand, the cause of subfertility may have indirectly affected patients 
in their choice to participate in the current study. Fertility problems that are hard 
to treat, e.g. endometriosis, or a severe oligospermia or azoospermia, often have 
a poor treatment outcome, not leading to the desired pregnancy. Although the 
patients participating in the current study did not show a higher occurrence of these 
diagnoses than the general subfertile population, the non-participants were more 
often nulliparous. Therefore, we cannot rule out that the prevalence of these hard-to-
treat cases might be more frequent in the non-participant group, and consequently 
also in the total RA population. Furthermore, there were more smokers among non-
participants than among participants. This may point toward a less healthy lifestyle, 
which in turn is associated with reduced conception rates.29 Details on smoking 
behaviour, like package years, are missing in the PARA study, and could not be 
analysed further. However, even if all non-participants of whom we know they had 
had fertility work-up or fertility treatments had another diagnosis than unexplained 
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subfertility, still the percentage of subfertile RA patients with unexplained subfertility 
would be higher than in the subfertile part of the general population.
In conclusion, our finding that unexplained subfertility is diagnosed more often in 
female RA patients than in the general population supports the idea that RA related 
factors are causally involved in subfertility in women with RA. Unexplained subfertility 
was associated with the periconceptional use of NSAIDs. Despite the higher incidence 
of subfertility in women with RA, the outcome of fertility treatments in these women 
appears favourable.  In future research on fertility in RA, attention should also be given 
to intercourse frequency and sexual problems, since these are scarcely studied in RA 
patients trying to conceive. In daily practice, when an RA patient wishes to conceive, 
NSAIDs should be avoided, and early consultation with an expert rheumatologist 
and a fertility specialist should be considered to optimize the patient's chance of a 
complete family. 
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Objective: To study the association between miscarriage in rheumatoid arthritis 
(RA) patients and serologic findings, disease activity, and antirheumatic drug 
treatment, and to study disease activity and reproductive outcomes after a 
miscarriage.
Methods: Within a nationwide prospective cohort study (Pregnancy-
Induced Amelioration of RA study), patients with RA were followed up from 
preconception until 6 months after delivery or miscarriage. Univariate and 
logistic regression analyses were performed to assess variables of interest, 
with covariates included in the models if the P value for association with 
miscarriage was <0.20 and subsequently excluded if the P value was>0.10.
Results: Amongst 162 pregnancies, 28 miscarriages occurred (17.3%; 95% 
confidence interval 12.2-24.0%). Women who miscarried were older than 
women with an ongoing pregnancy. Women who miscarried tended to be 
more often positive for anti-citrullinated protein antibodies (ACPAs), to have 
higher disease activity scores, and to have more often received methotrexate 
(MTX) therapy in the past. Logistic regression showed a tendency toward a 
higher likelihood of miscarriage in association with increasing age (P=0.065), 
and presence of ACPAs (P=0.092).
After miscarriage, 33% of women had a flare of RA. Within 1 year, 68% of 
women became pregnant again, 14% stopped trying to conceive, and 11% were 
lost to followup. The Live birth rate of the subsequent pregnancy was 90%.
Conclusion: The miscarriage rate in the PARA cohort is comparable to that 
in the general population. Due to the low frequency of miscarriages in this 
study, the associations between miscarriage in RA and the presence of ACPAs, 
disease activity and MTX use did not reach statistical significance. Within 
1 year after miscarriage, the majority of patients who continued trying to 
conceive achieved a pregnancy resulting in a live birth.





Rheumatoid arthritis (RA) and female reproduction have been linked in the literature 
for decades. It has been shown that RA often attenuated during pregnancy, while 
disease flares occur during the postpartum period.1 Furthermore, fertility is often 
impaired in female RA patients and is associated with disease activity and treatment 
with antirheumatic drugs.2,3   
However, with regard to the frequency of miscarriages in patients with RA, results 
have varied greatly. Whereas some studies have not shown an increased miscarriage 
rate in RA patients,4-6 others have demonstrated a signifi cant increase in miscarriage 
rates both before and after disease onset.3,7,8 Recently, a Norwegian birth registry 
study showed a signifi cantly higher risk of miscarriage in women with RA compared 
to the general population.8 The risk of recurrent miscarriage does not seem to be 
increased in RA, as no markedly increased numbers of miscarriages have been found 
in individual women.5,7 
Miscarriages may be the result of disturbed inflammatory mechanisms. In humans, 
about one-half of embryo implantations do not result in a successful pregnancy. This 
may be attributed to not only genetic factors or metabolic abnormalities of the embryo 
but also to poor uterine receptivity.9 A successful implantation may be facilitated by 
local injury of the endometrium, and more specifi cally, by an inflammatory reaction 
to such endometrial injury.9 Therefore, inflammation, as well as antiinflammatory 
treatment, may play a role during implantation and early pregnancy in women with 
chronic inflammatory conditions such as RA.
Since miscarriages in RA have thus far been retrospectively assessed, no detailed 
information on patients’ disease activity prior to conception has been reported. 
Moreover, reports on the preconception use of antirheumatic medications and rates 
of miscarriages may be biased. Therefore, the association between these factors and 
the occurrence of miscarriages in RA remains unclear. Miscarriages before the onset 
of RA are associated with more severe joint damage over time after diagnosis.10 What 
happens to RA disease activity during the months directly after a miscarriage is not 
known. 
Within a nationwide prospective cohort on pregnancy in RA, we studied the 
occurrence of miscarriage in women with RA and its association with serologic 
fi ndings, disease activity, and periconceptional use of antirheumatic drugs. In 
addition, we assessed the course of RA after miscarriage and the occurrence of 
subsequent pregnancies.





This study was performed within the Pregnancy-induced Amelioration of RA (PARA) 
study, a nationwide prospective cohort study in the Netherlands.1 From 2002 to 
2008, RA patients who wanted to become pregnant or were in their first trimester of 
pregnancy were invited by their attending rheumatologist to participate. Patients had 
to fulfill the American College of Rheumatology 1987 revised criteria.11 According to 
current guidelines, patients were required to have stopped teratogenic medications, 
such as methotrexate (MTX), at least 3 months before trying to conceive to be eligible 
for the study. Informed consent was acquired from all patients. The study was 
approved by the Erasmus Medical Center medical ethics review board.
For the current study, all patients who were enrolled preconceptionally were included. 
If patients participated at least twice in the PARA study, only the first episode was 
included.
Data
During the study, patients were visited preconceptionally, during each trimester of 
pregnancy, and 3 times (6, 12, and 26 weeks) after delivery. When patients miscarried, 
they were also visited at 6, 12, and 26 weeks following their pregnancy loss. 
Pregnancies were confirmed by the patients with a positive urine pregnancy test 
result. Miscarriage was defined as a loss of pregnancy before 16 completed weeks of 
gestation. 
At each visit, patients were interviewed by a research team member to obtain 
information on obstetric history and medication use. The level of disease activity was 
measured  using the Disease Activity Score in 28 joints (DAS28)12 based on 3 variables: 
the swollen, tender joint count, and C-reactive protein (CRP) level.1  
To determine the change in disease activity after miscarriage, we calculated the 
difference between the preconception DAS28 and DAS28 at 6, 12, and 26 weeks after 
miscarriage. We defined deterioration of RA as severe or moderate flares, defined 
as a reverse improvement response according to the European League Against 
Rheumatism response criteria for disease activity,13 which is independent of the 
baseline DAS28.1
Finally, levels of CRP, presence of rheumatoid factor (RF) and presence of anti-
citrullinated protein antibodies (ACPAs) were determined, as described previously.2





The primary outcome was the occurrence of a miscarriage before a gestational age 
of 16 weeks. The 9 variables of interest were maternal age at conception, presence 
of RF (at enrollment), presence of ACPAs (at enrollment), preconception DAS28, 
periconception use of nonsteroidal antiinflammatory drugs (NSAIDs) (daily or weekly 
during the preconception visit), use of sulfasalazine, use of prednisone, past MTX use, 
and total number of disease-modifying antirheumatic drugs (DMARDs) (current and 
past).
Differences between women who miscarried and women with an ongoing pregnancy 
were compared using Student's t-test or Fisher's exact test, as appropriate. Disease 
activity scores before conception and after miscarriage were compared using 
a paired t-test. Two-sided P values less than 0.05 were considered signifi cant. 
Multivariate analysis was performed using logistic regression with purposeful 
selection of covariates, with a P value of <0.20 used as the signifi cance level for 
inclusion, and subsequent exclusion of covariates based on a P value of >0.10.14 
The statistical package used was STATA/SE 13.1 (StataCorp).
RESULTS
Characteristics of the patients
There were 239 preconception visits within the PARA study, of which 58 did not result 
in a pregnancy within the followup period. Of the women who became pregnant, 13 
participated twice and 2 women participated 3 times. Only their fi rst study episode 
was used. Two patients were excluded: 1 patient had a molar pregnancy, and 1 patient 
had a pregnancy loss after intrauterine treatment during a twin pregnancy. There 
were 162 pregnancies for analysis.
The baseline characteristics of the patients are shown in Table 1. Eighty-two patients 
(50.6%) had already experienced at least one pregnancy, Of whom 22 (26.8%) had 
experienced one or more miscarriages in the past. During the analyzed study episode, 
28 women (17.3%; 95% confi dence interval 12.2%–24.0%) had a miscarriage: 
14 miscarriages occurred in the second month of pregnancy (range 5.6–8.6 weeks), 
9 miscarriages in the third month (9.3–11.9 weeks), and 5 miscarriages after 13 
weeks of gestation (13.7–14.7 weeks). One woman had miscarried once before, and 1 
woman had 3 previous miscarriages. There were no pregnancy losses between 16 and 
20 weeks of gestation.
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Table 1 - Baseline characteristics of the study patients (n = 162)
Variable Value Patients with missing variables, no. (%)
Age, mean ± SD years 32.3 ± 3.9 1 (0.6)
Never been pregnant, no. (%) 80 (4 9.4) -
Previous miscarriages, no. (%)
1 15 (9.3) -
2 5 (3.1) -
3 2 (1.2) -
Smoking, no. (%)† 21 (13.0) 2 (1.2)
Duration of RA, median (IQR) years 4.9 (2.6 - 10.6) 2 (1.2)
RF positive, no. (%) 114 (70.4) 1 (0.6)
ACPA positive, no. (%) 103 (63.6) 1 (0.6)
Erosions, no. (%)‡ 86 (53.1) 29 (17.9)
DAS28, mean ± SD 3.65 ± 1.14 1 (0.6)
Medication use, no. (%)
MTX in past 114 (70.4) -
NSAIDs periconception 47 (29.0) -
Sulfasalazine periconception 54 (33.3) -
Prednisone periconception 60 (37.0) -
Cumulative DMARDs§
None 17 (10.5) -
1 42 (25.9) -
2 54 (33.3) -
3 34 (21.0) -
≥4 15 (9.3) -
Biologic drugs¶
Past 23 (14.2) -
  Current 7 (4.3) -
* RA = rheumatoid arthritis; IQR = interquartile range; RF = rheumatoid factor; ACPA = anti-citrullinated 
protein antibody; DAS28 = Disease Activity Score in 28 joints; NSAIDs = nonsteroidal antiinflammatory drugs.
† Smoking status (yes/no) during the preconception period, as reported by the patient.
‡ Presence of erosions, as reported by the patient.
§ Cumulative number of different disease-modifying antirheumatic drugs (DMARDs) taken prior to 
the preconception visit, including both conventional DMARDs (methotrexate (MTX), sulfasalazine, 
hydroxycholorquine, gold, prednisone, azathioprine, and leflunomide) and biologic agents.
¶ Use of biologic drugs (etanercept, adalimumab, anakinra, and infliximab) in the past, or current use of 
biologic drugs (etanercept, adalimumab, and anakinra) during the preconception period.
Univariate analysis
Univariate analyses with the 9 variables of interest showed that women who 
miscarried were significantly older (mean ± SD age 33.9 ± 3.9 years) than women with 
an ongoing pregnancy (age 32.0 ± 3.8 years; P = 0.022) (Table 2). A larger proportion 
of women who miscarried were ACPA positive compared to those who had not 
miscarried (82% versus 60%), although the difference was not significant (P = 0.058). 




The DAS28 tended to be higher in women who miscarried (mean ± SD 3.92 ± 0.94 
versus 3.59 ± 1.17 in women who had not miscarried; P = 0.166), and more women 
with a miscarriage had received MTX therapy in the past (82% versus 68%; P = 0.174). 
There were no signifi cant differences in RF positivity, periconception use of NSAIDs, 
sulfasalazine use, prednisone use, and median cumulative number of DMARDs.
Table 2 - Univariate analysis of covariates in patients with rheumatoid arthritis who did and those who did not 
experience miscarriage*
Miscarriage  
Variable Yes (n = 28) No (n = 134) P
Age, mean ± SD years 33.9 ± 3.9 32.0 ± 3.8 0.022†
Missing, no. 0 1 –
RF positive, no. (%) 22 (79) 92 (69) 0.478‡
Missing, no. - 1 –
ACPA positive, no. (%) 23 (82) 80 (60) 0.058‡
Missing, no. - 1 –
DAS28, mean ± SD 3.92 ± 0.94 3.59 ± 1.17 0.166†
Missing, no. - 1 –
Medication use
MTX in past, no. (%) 23 (82) 91 (68) 0.174‡
NSAIDs periconception, no. (%) 6 (21) 41 (31) 0.371‡
Sulfasalazine periconception, no. (%) 10 (36) 44 (33) 0.827‡
Prednisone periconception, no. (%) 11 (39) 49 (37) 0.473‡
Cumulative no. of DMARDs, median (IQR)§ 2 (1–3) 2 (1–3) 0.461¶
* RF = rheumatoid factor; ACPA = anti-citrullinated protein antibody; DAS28 = Disease Activity Score in 28 
joints; MTX = methotrexate; NSAIDs = nonsteroidal antiinflammatory drugs; DMARDs = disease-modifying 
antirheumatic drugs; IQR = interquartile range.
† By Student's t-test.
‡ By Fisher's exact test.
§ Including biologic agents.
¶ By Mann-Whitney U test.
Multivariate analysis
We performed logistic regression analysis with the occurrence of miscarriage as the 
dependent variable and maternal age, ACPA positivity, DAS28 and previous MTX use 
as independent variables. Two patients who did not miscarry had missing variables 
and were excluded from the analysis. None of the variables showed a statistically 
signifi cant change in the risk of miscarriage. Two variables (DAS28 and past MTX use) 
had a subsequent P value for association with miscarriage of >0.10, and were therefore 
omitted from the model. After omitting the DAS28 (P = 0.227) and subsequently 
excluding past MTX use (P = 0.113) as independent variables, none of the remaining 
variables (increasing age and presence of ACPAs) showed any statistically signifi cant 
effect (P = 0.065 and P = 0.092, respectively) (Table 3). 
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Table 3 - Logistic regression  analysis of associations with miscarriage in patients with rheumatoid arthritis*
Variable OR 95% CI
Complete model
Age per year 1.11 0.99–1.25
ACPA positive 2.49 0.86–7.20
DAS28 per point 1.27 0.86–1.88
MTX use in past 2.52 0.86–7.36
Reduced model
Age per year 1.12 0.99–1.25
ACPA positive 2.47 0.86–7.08
* None of the odds ratios (ORs) were significant at P < 0.05.
95% CI = 95% confidence interval; ACPA = anti-citrullinated protein antibody; DAS28 = Disease Activity Score 
in 28 joints; MTX = methotrexate.
Followup after miscarriage
Twenty-one women were revisited after miscarriage. Six weeks after miscarriage, disease 
activity was measured in 19 women. The mean ± SD DAS28 was 4.3 ± 0.88, which was 
higher than the preconception DAS28 of 3.9 ± 1.0 in these women, but the difference was 
not significant (P = 0.064). Six of these women (32%) had experienced a moderate disease 
flare by 6 weeks after miscarriage. There were no severe flares. Nineteen women were 
visited again 12 weeks after miscarriage. At that time point, the mean ± SD DAS28 was 
4.1 ± 1.3, and an additional woman had experienced a moderate flare, resulting in a total 
of 7 (33%) of 21 women who had experienced a flare of RA between the preconception 
period and 3 months after miscarriage. Two patients had to put their efforts to conceive 
on hold, because they had restarted treatment with MTX or etanercept. No new flares 
had occurred in the 10 women who were revisited 6 months after miscarriage. 
After they miscarried, 4 women (14%) stopped trying to conceive and 3 women (11%) 
were lost to followup. All of the remaining women (21 (75%) of 28) conceived after the 
miscarriage. Nineteen women became pregnant again within 1 year after miscarriage. 
Two women achieved pregnancies after 20 and 47 months respectively. Two women 
(10%) experienced one more miscarriage, but thereafter each had a live birth in the 
subsequent pregnancy. 





In this study, 17% of pregnancies in RA patients ended in a miscarriage. Women with 
RA who miscarried were older and tended to be more often ACPA positive, to have 
higher disease activity, and to more often have been treated with MTX in the past. 
After miscarriage, one-third of women experienced a disease flare. In total, 75% of 
women with a previous miscarriage conceived again and delivered a live-born baby. 
The miscarriage rate of 17% in the PARA cohort, which is comparable to that in the 
general population (11-22%),15  is probably an underestimation of the true miscarriage 
rate in female RA patients. All pregnancies in our analysis were planned pregnancies, 
in contrast to those in prior retrospective studies, many of which often also included 
unplanned pregnancies, which were generally associated with  a less healthy lifestyle. 
Moreover, unplanned pregnancies in RA may be associated with postconception use 
of teratogenic medications such as MTX, and therefore these patients have a higher 
risk of miscarriage.16 In the PARA cohort, there is a known healthy cohort effect,17 since 
the cohort contains fewer smokers and the education level is higher than that in the 
general population. Furthermore, a considerable number of women in this study 
had already had already had a previous pregnancy, most of which were ongoing. 
Therefore, the a priori chance of establishing a subsequent ongoing pregnancy was 
probably already higher in this selected group. 
This is the fi rst study that measured disease activity during the preconception period 
in women with a subsequent miscarriage. The association between an increasing 
DAS28 and the occurrence of miscarriage was not signifi cant. However, since both 
ACPA positivity and previous MTX treatment, both of which are markers of more 
active disease, showed an association with the occurrence of miscarriage, it is likely 
that disease severity increases the risk of miscarriage in RA patients. This is also in 
concordance with current fi ndings in the literature on embryo implantation and 
pregnancy loss, which describes physiological inflammatory reactions within the 
endometrium, a fi nding that seems important in attempting to achieve successful 
embryo implantation and decidualization.9,18 Active RA may increase the risk 
of pregnancy loss through disturbance of decidualization. Moreover, repeated 
implantation failures due to immune imbalances may explain the association of active 
RA with subfertility.2  Furthermore, the inflammatory reactions in the endometrium 
may also be altered by antirheumatic medications, although we did not fi nd any 
statistically signifi cant associations with antirheumatic treatments in this study. 
48760 Jenny Brouwer.indd   67 20-12-17   09:44
Chapter 4
68
MTX, a folic acid antagonist, can be a disruptor of fetal development, and therefore it 
can potentially increase the miscarriage rate. However, a recent study on pregnancy 
outcomes after MTX use showed that there was no increased risk of miscarriage 
after preconceptional MTX use.16 To be eligible for the PARA study, patients who had 
been taking MTX had to stop the drug at least 3 months before trying to conceive. 
Therefore, it is unlikely that MTX itself has a causal relationship with the occurrence 
of miscarriage in this cohort. 
The percentage of patients who had a flare of RA within 6 or 12 weeks after their 
miscarriage was comparable to the percentage of patients with a flare after delivery.1 
However, patients who miscarry do not benefit from the attenuation of RA that often 
occurs in the second and third trimesters of pregnancy.1 Furthermore, many patients 
who delivered subsequently restarted or intensified antirheumatic drug treatment, 
whereas patients who had a miscarriage often could not be treated optimally, because 
they were again actively trying to conceive. Because of the increase in disease activity in 
a period of less- intensive antirheumatic treatment, flares after miscarriage may result 
in not only disability and long-term joint damage but also reduced fertility.2 
Although the PARA study is thus far the world's largest prospective cohort on pregnancy 
in RA, the associations found did not reach statistical significance due to the relative low 
frequency of miscarriages in the study. This also limited the possibilities for multivariate 
analysis. Nevertheless, this is the only known cohort of female RA patients with clinical 
information, such as medication use and disease activity scores, available during the 
preconception period. Since the presence of ACPA, past use of MTX, and disease activity 
scores all tend to be associated with the occurrence of miscarriage, it is plausible that RA 
patients with more severe disease have a higher risk of miscarriage. 
In conclusion, miscarriage rates in RA patients are comparable to those in the general 
population. The observed associations between miscarriages and the presence 
of ACPAs, disease activity, and MTX use were not significant.  Within 1 year after 
miscarriage, the majority of patients who continued trying to conceive achieved a 
pregnancy resulting in a live birth.
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Objective: Fertility is reduced in women with rheumatoid arthritis (RA), 
even before diagnosis. This may be due to a diminished ovarian reserve. The 
current study examined serum levels of anti-Müllerian hormone (AMH), 
the most reliable endocrine marker for ovarian reserve, in early RA patients, 
and the influence of disease activity and methotrexate (MTX) use on AMH 
concentrations. 
Methods: Serum AMH levels were measured in 72 women with recent-onset 
RA ages 18–42 years and compared to 509 healthy women. The association 
between AMH and rheumatoid factor (RF), anti-cyclic citrullinated peptide 
(anti-CCP), erosions, C-reactive protein (CRP) level, disease activity (Disease 
Activity Score in 28 joints (DAS28)), and use of MTX was assessed. 
Results: At diagnosis, age-adjusted serum AMH levels did not differ 
significantly between patients and controls (P = 0.254). AMH levels were not 
related to the presence of RF (P = 0.487), anti-CCP (P = 0.686), or erosions (P = 
0.350), and showed no significant correlation with CRP levels (r = -0.207, P = 
0.083) or disease activity scores (DAS28, r = 0.007, P = 0.955). After 6 months 
of treatment, AMH levels in patients (n = 53) were lower than at the time of 
diagnosis (P < 0.001), but did not differ from controls (P = 0.741). There was 
no significant difference in AMH values after 6 months of treatment between 
patients who did (n = 31) or did not (n = 22) receive MTX (P = 0.287). 
Conclusion: AMH levels in women with early RA are comparable to those of 
healthy controls, indicating that the reduced fertility in this patient group 
is not caused by diminished ovarian reserve. AMH levels are not affected by 
disease activity or by short-term MTX use. 
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Rheu matoid arthritis (RA) can already be manifest in women during their reproductive 
years and might therefore reduce the ability to have children. Female RA patients 
experience more fertility problems compared to healthy controls, resulting in a longer 
mean time to pregnancy.1-3 A reduced fertility seems to be present before diagnosis in 
female RA patients.1 Since, on average, women with RA appear to reach menopause at 
an earlier age compared to controls,1 the question is raised whether reduced fertility 
in women with RA is related to a compromised ovarian reserve. 
In fertility clinics the ovarian reserve, which constitutes the number of primordial 
follicles, is estimated using serum anti-Müllerian hormone (AMH) levels. AMH 
is a member of the transforming growth factor (TGF)-β family and is produced 
in the ovary by granulosa cells of early developing follicles.4 In both healthy and 
subfertile women, there is a strong correlation between serum AMH levels and the 
number of developing follicles in the ovaries, which declines with advancing age 
until the follicle pool is nearly depleted and the woman enters menopause. Due to 
this gradual decrease of quantity, which seems to go hand in hand with a decrease 
in quality of the oocytes harboured by the ovarian follicles, a woman will become 
infertile approximately ten years before she will enter menopause. The age at which a 
woman reaches menopause, as well as the preceding period of decreased fertility and 
infertility, varies greatly among women. At present, serum AMH is the most reliable 
predictor for the age at which a woman will enter menopause.5 
Little is known about the effect of disease activity, parameters of inflammation or use 
of anti-rheumatic drugs on measurement of serum AMH levels.
Since RA patients who try to conceive use adjusted, and often less effective, 
medication, they frequently have increased disease activity. Thus far, no reports on 
the effect of RA disease activity on serum measurements of AMH are known.
Preferably, women with RA who want to conceive should be screened for increased 
risk of subfertility before alteration or cessation of medication, so they can be referred 
to a gynecologist in due time and the time to pregnancy will be as short as possible. 
Since many of these patients use methotrexate (MTX), nowadays the fi rst choice drug 
in newly diagnosed RA, the effect of this potentially harmful drug on AMH levels 
should be studied.
The aim of this study therefore is to compare serum AMH concentrations between 
women with early RA and healthy controls, and to assess the influence of parameters 
of disease activity and the use of MTX on serum AMH levels in women with RA in 
childbearing age.





Patient data were derived from the Rotterdam Early Arthritis Cohort (REACH), a 
prospective cohort study in the greater Rotterdam area which was started in July 2004 
and is still ongoing.6 Enrolled patients had joint complaints for less than 12 months, 
which were not explained by trauma or overexertion. They did not use any anti-
rheumatic medication before enrolment. The Erasmus MC medical ethical review 
board approved the study protocol and a written informed consent was acquired 
before inclusion. Patients were examined at several visits, including the first visit (T0) 
and 6 months later (T6). Patient characteristics, general history, disease activity scores 
and drugs prescribed were registered. When available, serum samples for each visit 
were stored. X-rays of hands and feet were made at baseline and assessed for bony 
erosions. 
For the current study, all women aged 18 to 42 years fulfilling the 2010 ACR/EULAR RA 
classification criteria were included.7 Serum samples from T0 and T6 visits were used. 
Controls
An existing control population of healthy females was used.8 From this population, all 
women aged 18 to 42 years were selected (n=509). All controls had regular menstrual 
cycles ranging between 25 and 35 days or were proven fertile. Twenty-nine percent 
of controls had ever been pregnant, for 60% this is unknown. No additional fertility 
assessments were available. Controls did not use any hormones or oral contraceptives 
during the three months prior to blood sampling. In case of proven fertility, blood 
sampling was at least six months after delivery. Sampling was performed randomly 
during the menstrual cycle.8
Measurements
Disease activity was scored using the Disease Activity Score with a 28 joint count 
(DAS28). Serum samples were stored at -80° Celsius. Laboratory measurements 
included IgM-rheumatoid factor (RF) (enzyme-linked immunosorbent assay (ELISA)), 
anti-cyclic citrullinated peptide (anti-CCP), (Elia CCP on immunoCAP 250; Phadia 
Freiburg, Germany), C reactive protein (CRP) levels (mg/L) (local standards) and 
AMH levels (g/L) (in-house double-antibody ELISA (commercially available as GenII 
Beckman Coulter, Beckman Coulter, Inc., Webster, Texas)). The range of the AMH 
standards used in the in-house AMH assay was 0.037-5 ng/mL.8
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Differences between groups were calculated using Student's t-test or Mann 
Whitney-U test for continuous variables and Fisher's exact test for categorical 
variables. Univariate analysis of covariance (ANCOVA) was performed to adjust for 
age differences between groups. Correlations between AMH and CRP and DAS28 
were assessed by the partial correlation coeffi cient, correcting for age. Differences 
between T0 and T6 within subjects were studied using the paired samples t-test or 
the Wilcoxon signed ranks test. The proportional change in AMH levels between T0 
and T6 was calculated as AMH(T6)/AMH(T0). Linear regression was performed to 
study the effect of different variables on proportional AMH change.
Reference curves for serum AMH levels in controls as function of age were calculated 
from a linear regression model using a natural cubic spline fi tted on log-transformed 
AMH values of the control group.8
Values are represented as mean ± standard deviation or median (interquartile range). 
Two-sided p-values <0.05 were considered signifi cant. Statistical package used is 
SPSS Statistics 18.0.0 (IBM Corp., Armonk, N.Y., USA).
RESULTS
Patients
Between July 2004 and February 2011 174 women aged 18 to 42 years were enrolled 
in the REACH. Of the enrolled women, 95 (55%) fulfi lled the 2010 ACR/EULAR RA 
classifi cation criteria. Three of them were diagnosed psoriatic arthritis, but still 
fulfi lled the classifi cation criteria and were included in the analysis. One patient had 
a history of unilateral ovariectomy because of severe endometriosis and was excluded 
from the study. The fi rst (T0) and second (T6) visits were included in the analysis. 
Serum samples from T0 were available for 72 women whereas 53 of them had also 
serum stored at T6. The median time between the two visits was 182 (175-189) days.
The patients with available serum at T0 did not differ from patients without available 
serum (n=22) concerning age, BMI, symptom duration, CRP, or proportion of patients 
positive for RF, anti-CCP or erosions. At T0, included patients had a signifi cantly lower 
mean DAS28 of 4.52±1.29 compared to 5.19±1.05 in patients with no serum available 
(p=0.032) (table 1). Information on obstetric history was available in 50% of patients. 
Twenty-fi ve percent had ever been pregnant. No additional data on fertility problems 
were available. 
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Table 1. Patient characteristics at time of diagnosis*
  Patients for analysis Patients without available serum**
(n=72) (n=22) P-Value
Age - years 35.1 (30.1 – 39.2) 34.4 (29.6 – 38.7) 0.681†
BMI - kg/m2 24.2 (21.9 – 28.3) 23.7 (22.1 – 32.7) 0.531†
  Missing 2 2
Duration of symptoms - days 115 (67 – 182) 124 (75 – 306) 0.500†
RF positive - no. (%) 33 (46) 8 (47) 1.000‡
  Missing - 5
Anti-CCP positive - no. (%) 39 (54) 7 (41) 0.422‡
  Missing - 5
CRP - mg/L 7.0 (3.3 – 16.0) 11.0 (4.0 – 20.0) 0.167†
DAS-28 - mean (± SD) 4.52 (±1.29) 5.18 (±1.07) 0.032§
Erosions positive - no. (%) 10 (14) 2 (9) 0.726‡
*Except where indicated otherwise, values are the median (interquartile range).
**Patients without available serum at T0 were excluded from further analyses. 
BMI = body mass index, RF = rheumatoid factor, anti-CCP = anti-cyclic citrullinated peptide, CRP = C-reactive 
protein, DAS-28 = disease activity score with a 28 joint count. 
P-values indicate differences between the two groups, as calculated by (†) Mann Whitney-U test, (‡) Fisher's 
exact test and (§) Student's t-test
AMH at time of diagnosis
At T0, the median age in patients was higher than in controls (35.1 (30.1-39.2) and 29.4 
(23.8-34.3) years respectively, p<0.001). BMI did not differ significantly (24.2 (21.9-28.3) 
and 22.9 (21.2-25.7) kg/m2, p=0.063). Median AMH values were 1.71 (0.81-4.39) g/L in 
patients and 2.82 (1.64-4.38) g/L in controls. When adjusted for age, AMH values did 
not differ significantly between patients and controls (p=0.254). Eight patients (11%) 
had AMH levels below the 10th percentile of controls (figure 1A).
There was no significant difference in AMH levels, adjusted for age, when comparing 
RF positive with RF negative women (p=0.487). No differences in AMH concentrations 
were found between anti-CCP positive and negative women (p=0.686). AMH levels 
were not significantly different when erosions were present (p=0.350). Finally, there 
was no significant correlation between AMH and either CRP (r=-0.207, p=0.083) or 
DAS28 (r=0.007, p=0.955). 
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Figure 1. (A) Serum anti-Müllerian hormone (AMH) levels in women with recent onset rheumatoid arthritis at 
time of diagnosis (T0) are comparable to a healthy control population. (B) Serum AMH levels in women with 
recent onset rheumatoid arthritis six months after diagnosis (T6), differentiating between patients who did or 
did not receive methotrexate (MTX) treatment during these six months. The lines represent the 10th, 50th and 90th 
percentile lines of predicted AMH values in healthy controls.
AMH six months after diagnosis
Blood samples were available for both visits in 53 patients. The mean value of DAS28 
decreased signifi cantly during six months from 4.54±1.29 to 3.02±1.38 (p<0.001), as 
did CRP levels (7.0 (4.0-18.0) to 5.0 (2.0-9.4) mg/L, p=0.008).
AMH levels at T6 were signifi cantly lower than at T0 (1.92 (0.84-3.75) and 2.57 (0.90-
5.30) g/L respectively, p<0.001). AMH levels at T6 were not different from those in 
controls (p=0.741). Five women (9%) had AMH levels below the 10th percentile of 
controls. 
At T6, there was neither a signifi cant correlation between CRP levels and AMH (r=-
0.170, p=0.247), nor between DAS28 and AMH (r=0.084, p=0.563). 
Thirty-one out of 53 women (58%) were prescribed MTX at the fi rst visit in dosages of 
7.5-25 mg/week (mean dosage 20 mg/week). These women had signifi cantly higher 
CRP levels (8.0 (5.0-26.0) mg/L, p=0.022) and DAS28 values (4.91±1.38, p=0.009) at T0 
than those who did not receive MTX (CRP 4.5 (2.0-11.0) mg/L and DAS28 4.04±0.96). 
The proportion of RF positive women was higher in the MTX group (68% versus 23%, 
p=0.002). At T0, age (p=0.139), BMI (p=0.804), symptom duration (p=0.346) and age-
adjusted AMH levels (p=0.229) showed no signifi cant difference between the two 
groups.
After six months of treatment, age-adjusted AMH levels did not differ signifi cantly 
between MTX users and patients not using MTX (p=0.287). The proportional change 
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in AMH levels did not differ between the two groups (p=0.422) (figure 2), and was not 
dependent on age, DAS28, presence of RF or anti-CPP, and MTX use. AMH levels did 
not differ significantly either between patients using MTX and controls (p=0.394) or 
between patients without MTX and controls (p=0.657) (figure 1B).
Figure 2. The individual change in serum anti-Müllerian hormone (AMH) levels from time of diagnosis (T0) to six 
months later (T6) in (A) rheumatoid arthritis (RA) patients not using methotrexate (MTX) and (B) RA patients 
who are using MTX during the six months following diagnosis. The proportional change in time of AMH levels 
between the two groups shows no significant difference (p=0.422).
DISCUSSION
To our knowledge, this is the first study reporting on AMH serum levels in RA patients. 
Our results show that serum AMH concentrations in women with early RA are 
comparable to healthy controls. Serum AMH levels in early RA are neither influenced 
by parameters of disease activity nor by use of MTX. This study hereby provides an 
answer to Clowse et al., who suggest AMH as a marker to detect subclinical damage to 
the ovary during and after cyclophosphamide therapy, but point out that the impact 
of rheumatologic disease and anti-rheumatic drugs on AMH expression is unknown.9
Subfertility might already be present in RA patients at time of diagnosis.1 However, 
according to current results, this appears not to be due to a reduced ovarian reserve. 
As earlier menopause has especially been reported in RF positive RA patients,1 auto-
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immunity could play an important role in the early exhaustion of the primordial 
follicle pool. In RA, auto-antibodies like RF and anti-CCP can be found years before 
the disease becomes manifest.10 These auto-antibodies are thought to represent a 
subgroup of RA patients with most severe disease and the highest chance for extra-
articular manifestations. Therefore, in case a decreased ovarian reserve might already 
be present early after diagnosis, it is most likely to be found in this subgroup of patients. 
The results of this study however, do not confi rm the hypothesis of a decreased ovarian 
reserve at time of diagnosis in either anti-CCP or RF positive women.
Another possible explanation for early menopause is MTX, the fi rst choice drug for 
newly diagnosed RA patients. Women with RA who want to become pregnant may 
have been using MTX for a considerable amount of time. However, there is a lack 
of studies on the effect of long term low-dose MTX treatment on ovarian reserve in 
humans. In rats, daily administration of low (0.05 mg/kg) or high dose (0.15 mg/kg) 
MTX for 20 days showed a dose dependent loss of vaginal cyclicity, and hormonal 
changes towards post-menopausal values. Ovarian preantral and antral follicle 
growth was reduced. This was already apparent in low dose MTX treatment and 
became even more distinct in rats that received higher doses.11 However, in our study, 
there was no effect of MTX on AMH levels, suggesting that short term MTX does not 
affect ovarian reserve. Further research is needed to elucidate the effect of long-term 
low-dose MTX treatment on fertility in women with RA. Unfortunately, the number 
of premenopausal women in the REACH with a follow up of one or more years is too 
small to study the long term effects of MTX treatment on fertility in this group.
In current study, detailed information on obstetric and gynecologic history was 
available for a limited number of patients. Since it is reported that serum AMH levels 
are not altered by use of hormonal contraception or parity, this is highly unlikely 
that these missing data would affect the outcome of this study.12,13 Timing of blood 
sampling in the menstrual cycle was not available, but it has been shown that serum 
AMH levels do not differ signifi cantly throughout the menstrual cycle.14 
In conclusion, the current study shows that AMH levels in RA patients are not 
influenced by disease activity and MTX use. Furthermore, the results do not confi rm 
a reduced fertility based on a demise of the primordial follicle pool at time of 
diagnosis in women with RA, since the ovarian reserve, as measured by AMH levels, 
is comparable to the control group. Long term follow up of female RA patients should 
clarify the role of ovarian reserve and other clinical factors in subfertility in this patient 
group.
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Background: Subfertility, a time to pregnancy (TTP) longer than 12 months, 
is present in 40% of female rheumatoid arthritis (RA) patients who are 
actively trying to conceive. Since RA patients appear to reach menopause at a 
younger age, a lower ovarian reserve may explain the reduced fertility. Serum 
anti-Müllerian hormone (AMH) levels are the best proxy to measure ovarian 
reserve. Our objectives were to study AMH levels in female RA patients and 
determine the association of preconceptional serum AMH levels with TTP.
Methods: a post-hoc analysis was performed within patients of the 
Pregnancy-induced Amelioration of RA (PARA) cohort, who were assessed 
preconceptionally. Serum AMH levels were measured with the Ansh Labs pico 
AMH ELISA assay, and compared to an existing cohort of healthy controls.
Results: preconceptional serum was available in 209 women of the PARA cohort 
(aged 32.1±3.9 years), of whom 45% were subfertile in the current episode. The 
median AMH level was 2.5 ug/L (IQR 1.5–4.6). AMH levels were significantly 
lower compared to healthy controls (p<0.001), with 17% of patients having 
levels below the age-specific 10th percentile. Multivariable analysis showed a 
negative association of AMH with the presence of anti-citrullinated protein 
antibodies (ACPA) (p=0.009). AMH levels showed no significant association 
with TTP (p=0.26).
Conclusion: women with RA have lower AMH levels than healthy controls, 
and AMH levels were lower in ACPA positive patients. However, since 
preconceptional AMH levels were not associated with TTP, the reduced AMH 
levels do not explain the reduced fertility in RA patients.
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Rheumatoid arthritis (RA) is a chronic inflammatory auto-immune disease that 
not only affects the joints, but also has extra-articular manifestations. RA can 
already be manifest at reproductive age and might therefore reduce the ability to 
have children. Approximately 40% of female RA patients suffer from subfertility 
– a time to pregnancy (TTP) longer than 12 months despite regular unprotected 
intercourse – compared to 10-15% of women from the general population.1-3 
Overall, RA patients have less children and are more often nulliparous than non-
RA controls.4 
A longer TTP in RA patients has been associated with older age, no previous 
pregnancies, higher disease activity, and the periconceptional use of NSAIDs and 
prednisone.2 However, little is known about the ovarian function in RA patients and 
its effect on fertility. Since women with RA appear to reach menopause at a slightly 
younger age,4,5 and since several autoimmune disorders have been related to primary 
ovarian insuffi ciency,6,7 the ovarian follicle pool in female RA patients may be reduced 
at a relative early age. A recent small study has indeed reported results suggesting a 
reduced ovarian reserve in women with established RA.8 Since in general a woman 
becomes less fertile approximately 10 years before she experiences menopause, a 
younger menopausal age is related to an earlier decrease in fertility,9 reflected by a 
longer TTP or not achieving pregnancy at all.
 
The reduced fertility with increasing age is strongly correlated with the decline in 
number of follicles present in the ovary.9 The size of the primordial follicle pool 
can be estimated by measuring serum levels of Anti-Müllerian hormone (AMH), 
which is specifi cally produced by the granulosa cells of the small growing ovarian 
follicles.10,11 AMH levels are highest in early adulthood and decline with age, until 
they are undetectable around menopause.12 Unlike other hormonal markers for 
ovarian function, such as follicle stimulating hormone (FSH), fluctuations in serum 
AMH levels throughout the menstrual cycle are small.13 It should be noted that AMH 
expression in follicles may be downregulated, causing a discrepancy between AMH 
levels and the actual primordial follicle pool. For example, declined serum AMH levels 
during pregnancy have been reported.14-17  Still, at present, a woman's serum AMH 
level is the most reliable predictor for the age at which she will enter menopause.18 
Regarding fertility, AMH levels have been reported to add to the prediction of live birth 
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in assisted reproductive technology cycles, 19-22 and low serum AMH levels have been 
described to be associated with a reduced chance of natural conception,23 although 
conflicting results have been reported.24
To study the ovarian reserve in women with RA, we measured serum AMH levels 
in women with RA who had participated preconceptionally in a nationwide cohort 
study, and we studied the association of preconceptional AMH levels with subfertility 
in these women, as measured by TTP. 
METHODS
Patients
A post-hoc analysis was performed within the Pregnancy-induced Amelioration of RA 
(PARA) study, a nationwide prospective cohort from 2002-2010 from the Netherlands. 
Patients were recruited in 2002-2008 by their attending rheumatologist, when they 
had a diagnosis of RA according to the American College of Rheumatology (ACR) 1987 
classification criteria25 and were trying to conceive or were in their first trimester of 
pregnancy. Patients had to have a good understanding of the Dutch language.26 The 
PARA study was approved by the Medical Ethics Research Committee of the Erasmus 
MC, university medical center Rotterdam.
For the current study, only those patients were included in the analysis who were 
assessed during the preconceptional period. In patients who participated twice or 
more in the PARA study, only the first occurring preconceptional visit was selected.
Data collection
During the PARA study, patients were visited at their homes by a member of the 
research team. Assessments took place before conception (when possible), during 
each trimester of pregnancy, and 6, 12 and 26 weeks after delivery. At every visit, 
patients filled out questionnaires on obstetric history, medication use, health and 
daily functioning. Disease activity was measured, and a blood sample was drawn.26 
All data was collected in the PARA database. Variables used for analysis were: date 
of start trying to conceive, age at start trying to conceive, age at drawing of serum 
sample, duration of disease, occurrence of any previous pregnancies, presence of 
rheumatoid factor (RF), presence of anti-citrullinated protein antibodies (ACPA), 
preconceptional disease activity, patient-reported erosions, preconceptional use of 
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prednisone or sulfasalazine, preconceptional use of non-steroidal anti-inflammatory 
drugs (NSAIDs), and use of methotrexate in the past. 




Disease activity was measured using a tender and swollen joint count for 28 joints, 
combined with serum C reactive protein (CRP) levels (DAS28-CRP).27 Details on the 
measurement of RF and ACPA can be found in the original report on the PARA study.26
Serum samples were stored at -80°C. Serum AMH levels (ug/L or ng/ml) were 
measured using pico AMH assay developed by Ansh Labs (Houston,Texas, USA).28 The 
Limit of Detection (LoD) was 0.0012 ug/L.
Controls
Serum AMH values were compared to those of an existing healthy control group 
consisting of 554 adult women aged 18-47 years, who had regular menstrual cycles, 
and of whom the majority was proven fertile.12 Since serum AMH levels in the control 
group were reported as values measured with the GenII Beckman Coulter assay, a 
conversion factor was used to compare the AMH levels in the patient group to those 
in the controls:29  
AMH (pico AMH assay in ng/mL) = (1.45 * AMHGen II) + 0.32 
Statistics
Serum AMH levels were skewed to the right and were log-transformed for analysis. 
To make log-transformation possible, serum AMH levels below the LoD (0.0012 ug/L), 
were imputed by dividing the LoD by the square root of 2.30  Numbers of missing values 
were reported. Missing values were imputed using multiple imputation with chained 
equations. All variables of interest (see Data collection) that had missing values were 
included in the imputation, as well as all other variables intended to be put into the 
Cox proportional hazard analysis. Because of the survival nature of the data, also 
the event variable _d (occurrence of pregnancy) and the Nelson Aalen estimator 
(estimation of baseline hazard H0(t))  were included in the imputation procedure.
31 
Being outcome variables, missing values of _d and the Nelson Aalen estimator were 
not imputed.   
An analysis of covariance (ANCOVA) was performed to compare log-transformed AMH 
levels, corrected for age, between RA patients and controls. Associations of various 
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variables with AMH levels were tested separately using linear multiple regression 
on the log-transformed AMH values. A multivariable analysis was performed by 
entering all variables of interest into the multiple linear regression. Since AMH can be 
considered a proxy for ovarian age despite a woman's calendar age, the multivariable 
analysis was performed both with and without age as a covariate. 
To study the TTP, a Kaplan-Meier curve was drawn. To avoid negative values of TTP 
for women who conceived within the first menstrual cycle, the fictitious date of 
the positive pregnancy test was calculated by adding 28 days to the first day of the 
final menstrual period. The Cox proportional hazard analysis was performed with 
the occurrence of pregnancy as event variable. Aside from log-transformed AMH 
levels and age, covariables were selected on the basis of our previous study on TTP 
in RA: never been pregnant before, disease duration, presence of RF and ACPA, 
DAS28, preconceptional use of NSAIDs, of prednisone and of sulfasalazine, and past 
methotrexate use. Smoking was not included, since the percentage of smokers in 
the PARA study was low and had no effect on TTP in the previous study.2 Presence of 
erosions was added, as a measure for long term disease severity. In a second analysis, 
age was excluded, to study whether unadjusted AMH levels showed an association 
with TTP. 
P-values below 0.05 were considered statistically significant. Statistical software used 
is STATA 14.1 (College Station, Texas, USA).
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A preconceptional serum AMH was available in 209 patients within the PARA study 
(fi gure 1). Baseline characteristics and missing values are reported in table 1.
Figure 1 – flow diagram for available preconceptional patients within the PARA study
A pregnancy was achieved during follow-up after the preconceptional study visit 
in 159 women (76%). In 47 women (22 %) the episode did not result in a pregnancy, 
and 3 women (1.4%) were lost to follow-up without knowing whether a pregnancy 
was achieved. In the women who got pregnant, the median time to pregnancy since 
patients actively tried to conceive was 6.1 months (IQR 2.6 – 15.4 months). In women 
who did not achieve pregnancy, the median follow-up period was 17.3 months (IQR 
14.4 – 25.8 months). A Kaplan-Meier curve for time to pregnancy is shown in fi gure 2. 
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Table 1 - Baseline characteristics
 Variable Preconceptional
n=209
Age - years (mean ± sd) 
at start trying to conceive 31.7 ± 3.9
at study visit 32.1 ± 3.9




3 or more 7 (3.4%)
Previous miscarriages (n (%))
0 181 (87%)
1 20 (9.6%)
2 or more 8 (3.8%)
Disease characteristics
Duration of RA - years (median (IQR))
at start trying to conceive 4.1 (1.7 - 9.0)
at study visit 4.5 (2.0 - 9.4)
missing 2 (1.0%)
RF positive (n (%)) 153 (73%)
missing 2 (1.0%)
ACPA positive (n (%)) 137 (66%)
Presence of erosions (patient) (n (%)) 107 (51%)
missing 41 (20%)
DAS28-CRP at study visit (mean ± sd) 3.73 ± 1.17
missing 3 (1.4%)





NSAIDs (incl COX2 inhibitors) 94 (45%)
Biologics 8 (3.8%)
Ever used MTX (n (%)) 148 (71%)
  missing 1 (0.5%)
RA = rheumatoid arthritis, RF = rheumatoid factor, ACPA = anti-citrullinated protein antibody, DAS28-CRP = disease 
activity score using a 28 joint count and C-reactive protein, NSAIDs= non-steroidal anti-inflammatory drugs, COX2 = 
cyclo-oxygenase 2; 
* When using anti-rheumatic drugs, patients could be using more than 1 of the reported drugs.
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Figure 2 – Kaplan-Meier curve depicting the time to pregnancy in women with rheumatoid arthritis trying to 
conceive. T=0 is the moment indicated by the patients at which they fi rst had actively tried to conceive.
Ninety-four women (45%) were subfertile based on a time to pregnancy >12 months or 
a follow-up time >12 months without achieving a pregnancy. For six women (2.9%) it 
was unknown whether they fulfi lled the criteria for subfertility because it was unknown 
whether they achieved pregnancy during the follow-up (n=3), or because their follow-up 
time ended before they had been trying to conceive for 12 months (n=3).
Serum AMH levels and RA disease characteristics
The median preconceptional serum AMH level was 2.5 ug/L (IQR 1.5 – 4.6), with 1 
woman having an AMH level below the LOD. The individual preconceptional serum 
AMH levels were plotted in the nomogram created for healthy controls12 (fi gure 3). In 
36 women (17.2%) the AMH levels were below the 10th percentile for their age, in 94 
patients (45.0%) AMH levels were between the 10th and 50th percentile, in 73 patients 
(34.9%) between the 50th and 90th percentile, and in 6 (2.9%) of patients AMH levels 
were above the 90th percentile. ANCOVA with log-transformed AMH levels, showed 
signifi cant lower AMH levels, corrected for age, in patients compared to controls 
(p=<0.001).
Mono-variable analyses showed a signifi cant negative association of log-transformed 
AMH levels with increasing age (β= -0.070 (95%CI -0.11 ‒ -0.031), p=0.001) and the 
presence of ACPA (β= -0.38 (95%CI -0.71 ‒ -0.056), p=0.022) (table 2). Serum AMH 
levels were not associated with never having been pregnant before, disease duration, 
presence of RF, DAS28-CRP, presence of erosions, use of NSAIDs, use of prednisone, 
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sulfasalazine use, or past use of methotrexate. A multivariable linear regression 
of log-transformed AMH levels including all of the above covariates, showed a 
significant negative association with the presence of ACPA, both corrected for age (β= 
-0.47 (95%CI -0.89 ‒ -0.051), p=0.028), as well as uncorrected for age (β= -0.57 (95%CI 
-0.99 ‒ -0.14), p=0.009) (table 2).
Figure 3 – Preconception serum AMH levels in 209 women with rheumatoid arthritis trying to conceive, plotted 
against the 10th, 50th and 90th percentile of serum AMH values in healthy controls.12
AMH and time to pregnancy (TTP)
For the Cox proportional hazard analysis, the preconceptional study visit at which the 
first serum was drawn was considered as the start of follow-up.  Of the 209 women, 
205 women were included in the analysis. Four women were excluded because it was 
unknown whether pregnancy had occurred (n=3) or what the exact follow-up time 
was (n=1). Log-transformed AMH levels, corrected for age, were not significantly 
associated with TTP (HR 1.09 (95%CI: 0.94 – 1.27), p=0.26). A longer TTP was associated 
with older age (HR 0.96 per year (95%CI: 0.91 – 1.00), p=0.052), never having been 
pregnant before (HR 0.43 (95%CI: 0.30 ‒ 0.62), p<0.001), increasing disease activity 
(HR 0.85 per point of DAS28 (95%CI 0.73 ‒ 0.98), p=0.026), and preconceptional 
NSAIDs use (HR 0.5(95%CI: 0.40 ‒ 0.81), p=0.002) (table 3). An interaction term 
between age and AMH was not significant (p=0.20), and was not included in the 
model. When leaving age out of the model, the uncorrected AMH levels also showed 
no significant association with TTP (HR 1.14 (95%CI: 0.98 – 1.33), p=0.093) (data not 
shown).
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Table 2 - The association of anti-Müllerian hormone (AMH) levels (log-transformed) with disease related factors 




Beta 95% confi dence interval Beta 95% confi dence interval
Monovariable associations Uncorrected for age Corrected for age
Age - per year -0.070 -0.11 ‒ -0.031 ** -
Never been pregnant before 0.16 -0.15 ‒ 0.47 0.33 -0.28 ‒ 0.35
Disease duration - per year -0.022 -0.048 ‒ 0.004 -0.018 -0.044 ‒ 0.0074
RF positivity -0.040 -0.40 ‒ 0.32 0.033 -0.32 ‒ 0.38
ACPA positivity -0.38 -0.71 ‒ -0.056 * -0.29 -0.61 ‒ 0.036
DAS28-CRP - per point -0.012 -0.15 ‒ 0.12 -0.0020 -0.13 ‒ 0.13
Presence of erosions -0.24 -0.61 ‒ 0.14 -0.25 -0.61 ‒ 0.11
NSAIDs preconceptional 0.040 -0.28 ‒ 0.36 0.021 -0.29 ‒ 0.33
Prednisone preconceptional 0.031 -0.29 ‒ 0.35 0.014 -0.30 ‒ 0.32
Sulfasalazine 0.14 -0.18 ‒ 0.47 0.15 -0.17 ‒ 0.47
Past use of methotrexate 0.053 -0.29 ‒ 0.40 0.036 -0.30 ‒ 0.37
Multivariable analysis Uncorrected for age Corrected for age
Age - -0.061 -0.10 ‒ -0.020 **
Never been pregnant before 0.13 -0.19 ‒ 0.44 0.22 -0.30 ‒ 0.34
Disease duration - per year -0.022 -0.053 ‒ 0.0076 -0.18 -0.047 ‒ 0.012
RF positivity 0.30 -0.15 ‒ 0.76 0.30 -0.14 ‒ 0.75
ACPA positivity -0.57 -0.99 ‒ -0.14 ** -0.47 -0.89 ‒ -0.051 *
DAS28-CRP - per point 0.001 -0.14 ‒ 0.14 0.0080 -0.13 ‒ 0.15
Presence of erosions -0.085 -0.53 ‒ 0.36 -0.14 -0.57 ‒ 0.29
NSAIDs preconceptional 0.010 -0.33 ‒ 0.35 -0.001 -0.33 ‒ 0.33
Prednisone preconceptional -0.0004 -0.34 ‒ 0.34 -0.010 -0.34 ‒ 0.32
Sulfasalazine 0.17 -0.16 ‒ 0.50 0.18 -0.15 ‒ 0.50
Past use of methotrexate 0.11 -0.25 ‒ 0.47 0.095 -0.26 ‒ 0.45  
AMH = anti-Müllerian hormone (in ug/L), RF = rheumatoid factor, ACPA = anti-citrullinated protein antibodies, DAS28-
CRP = disease activity score with a 28 joint count and C-reactive protein, NSAIDs = non-steroidal anti-inflammatory 
drugs.
* p<0.05 ; ** p<0.01
DISCUSSION
In female RA patients trying to conceive, we found that preconceptional serum AMH 
levels, corrected for age, were lower than those in healthy controls. AMH levels were 
signifi cantly negatively associated with ACPA positive disease. Serum AMH levels did 
not show a signifi cant association with the TTP in RA patients, not even when used as 
a substitute for age.
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Table 3 - Cox regression for time to pregnancy counting from the moment of AMH measurement in women with 
rheumatoid arthritis who are trying to conceive (n=205)
Variable Hazard Ratio 95% confidence interval p-value
log(AMH) 1.09 0.94 ‒ 1.27 0.26
Age - per year 0.96 0.91 ‒ 1.00 0.052
Never been pregnant before 0.43 0.30 ‒ 0.62 <0.001
Disease duration - per year 0.99 0.96 ‒ 1.02 0.50
RF positivity 0.73 0.47 ‒ 1.15 0.17
ACPA positivity 1.12 0.71 ‒ 1.76 0.62
DAS28-CRP - per point 0.85 0.73 ‒ 0.98 0.026
Presence of erosions 1.57 0.87 ‒ 2.85 0.13
NSAIDs preconceptional 0.57 0.40 ‒ 0.81 0.002
Prednisone preconceptional 0.77 0.54 ‒ 1.10 0.16
Sulfasalazine 0.89 0.64 ‒ 1.26 0.52
Past use of MTX 1.12 0.77 ‒ 1.62 0.55
AMH = anti-Müllerian hormone (in ug/L), RF = rheumatoid factor, ACPA = anti-citrullinated protein antibodies, DAS28-
CRP = disease activity score with a 28 joint count and C-reactive protein, NSAIDs = non-steroidal anti-inflammatory 
drugs, MTX = methotrexate
The lower AMH levels in RA patients confirm recent findings in a small study on AMH 
levels in RA, where 33 RA patients had lower AMH levels than age-matched controls.8 
On the other hand, at the time of RA diagnosis, AMH levels have been found not to be 
significantly different from controls.32 Apparently, during the course of the disease, 
RA has a negative effect on the AMH levels. This is in line with studies on other chronic 
conditions reporting reduced AMH levels in women with cystic fybrosis,33 girls with 
newly diagnosed cancer,34 and women with Crohn's disease35 or systemic lupus 
erythematosus.36 Also in women with type 2 diabetes mellitus a reduced ovarian 
reserve has been reported, as reflected by elevated FSH levels and reduced antral 
follicle counts compared to controls.37 Overall, these findings support the hypothesis 
that the ovarian function is affected by a woman's overall health status.  Apparently, 
a woman's capacity to reproduce is compromised in times when the soma is less 
healthy. In women with RA, this is also reflected in the younger age at which they 
appear to reach menopause, as has been reported in a previous case-control studies.4,5 
Lower AMH levels, and the subsequently higher chance for early menopause may not 
only have implications for a woman's fertility, but also for her overall long term health, 
since women who reach menopause at a younger age have an ongoing unfavorable 
health state, with increased lifetime risk for conditions such as osteoporosis, and 
cardiovascular disease.6
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In agreement with the other study on AMH in established RA,8 we did not fi nd a 
signifi cant association of AMH levels with disease duration. However, we did observe 
a signifi cant association of lower AMH levels with the presence of ACPA, which has 
been related to a more severe disease responding poorer to anti-rheumatic therapy.38 
Possibly women with more severe RA have high levels of circulating cytokines or 
immune cells affecting the ovaries during active disease, or the long-term use of anti-
rheumatic drugs, such as methotrexate, affects the ovaries.39 However,  no signifi cant 
effect of past use of methotrexate on TTP in RA has been reported.2 Therefore, it will 
be interesting to analyze the effect of circulating cytokines and cumulative anti-
rheumatic drug use on AMH levels in women with RA in future studies. 
The comparison of AMH levels with controls has to be interpreted with caution. 
As explained in the methods section, the AMH levels in controls were previously 
measured using an assay by another manufacturer, and a conversion factor was 
applied.29 The use of conversion formulae for comparison of AMH levels from different 
assays has been debated. Especially with higher AMH levels, the precision of using 
regression equations decreases.29  However, the number of patients in our study with 
AMH levels around or above the 90th percentile of controls were low. Furthermore, the 
focus of our current report is on the lower AMH levels, and therefore less precision loss 
is to be expected. Indeed, using other conversion formulae that have been reported29 
still showed signifi cantly lower AMH levels in RA patients compared to controls. 
Another point of consideration is the lower limit of detection for the applied pico AMH 
assay. Replacement of very low AMH levels in our cohort with the conversed limit of 
detection of the older AMH assay used in the control group still showed signifi cant 
lower AMH levels in RA patients compared to controls (p<0.001, data not shown). 
Although AMH levels in RA patients were lower than in healthy controls, serum AMH 
levels did not show a signifi cant association with TTP. The reduced AMH levels may be 
explained by a diminished number of ovarian follicles, but may also be the result of a 
reduced expression of AMH by the individual follicles. Either way, the reduced AMH 
levels in women with RA do not appear to have a signifi cant effect on their conception 
chances. In a previous report that has shown low AMH levels to be a predictor of 
reduced fertility, selected patients were older, had been trying to conceive for a shorter 
period of time, pregnancy rates were higher, and AMH levels were dichotomized for 
analysis.23 Another report on healthy women of a younger age showed no reduced 
fertility when AMH levels were low.24 On the contrary, it did report an association of 
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high AMH levels with a longer TTP, which could be explained by patients with high 
AMH levels more often suffering from anovulation or other characteristics of the 
polycystic ovary syndrome, which is known to cause subfertility.24 In our study, AMH 
levels as a continuous variable showed a non-significant shorter TTP with increasing 
AMH levels. Splitting the AMH levels in quintiles comparing the lowest and highest 
AMH groups to the middle group, did not confirm the findings of these previous 
studies (data not shown).
Although AMH levels have not clearly been shown to predict a woman's TTP, many 
studies have shown that AMH levels are a reliable indicator for ovarian response after 
stimulation for artificial reproductive techniques, such as in vitro fertilization (IVF).40-
42. No studies on ovarian stimulation results in RA patients have been available thus 
far, but given the current results, patients with established RA undergoing IVF may 
have a lower oocyte yield than would be expected by age alone.
As we have shown previously, disease activity and the preconceptional use of NSAIDs, 
did have a significant effect on TTP, as did not having had a previous pregnancy.2 
However, in the previous study also periconceptional use of prednisone had a 
significant effect on TTP, which we could not confirm in the current analysis. The 
estimated hazard ratio for the occurrence of pregnancy in prednisone users versus 
non-users in the current study appeared higher than in the previous study, also when 
repeating the analysis with the same covariates as in the previous study (data not 
shown). A possible explanation for this difference lies in the selection of patients. 
Where the former study included also first trimester visits, the current study only 
included preconceptional visits. This selection was chosen, because AMH levels are 
known to be decreased during pregnancy.14-17 Comparing the baseline characteristics 
for our two studies, significantly more patients in the current study used prednisone 
or NSAIDs during the periconceptional period, and significantly less women used no 
anti-rheumatic drugs. Since TTP and the percentage of women without a previous 
pregnancy did not differ between the two studies, our current cohort does not seem to 
represent a less fertile selection than the previous study. Therefore, it is difficult to give 
a clear explanation for the difference in effect of prednisone on TTP. The advantage 
of the current exclusively preconceptional cohort is that such a study probably 
suffers less from recall bias of TTP and preconceptional use of anti-rheumatic drugs. 
Furthermore, possible effects of pregnancy on disease activity and serum AMH levels 
are excluded in this cohort.
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Concerning disease characteristics, our study cohort appears to be representative 
for patients with established RA. However, we have to consider the changes in 
management of RA since the end of the PARA study follow-up in 2010. Nowadays, 
anti-rheumatic treatment is based on treat-to-target guidelines. Moreover, so-called 
biologicals (such as tumor necrosis factor alpha blockers) are prescribed more often 
and also earlier in the disease course. Since several biologicals appear to be safe 
during pregnancy,43 they are also prescribed more often in women trying to conceive. 
Therefore, the current preconceptional patients will differ from the patients in the 
PARA cohort regarding disease activity and the use of anti-rheumatic drugs. New 
observational cohorts will have to address whether these changes in treatment have 
a positive effect on ovarian reserve, fertility and offspring in RA patients.
In conclusion, serum AMH levels are decreased in women with RA, and lower AMH 
levels show an association with ACPA positive disease, which is often related to a more 
severe disease state. However, preconceptional AMH levels are not associated with 
TTP in RA, and therefore cannot explain the reduced fertility in these patients. Since 
decreased AMH levels may result in an early occurrence of menopause, further study 
in RA patients should clarify the long-term effect of RA and anti-rheumatic drugs on 
the age at which menopause occurs.
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Background: In several chronic conditions an early decline of ovarian function 
is found. Whether the same holds true for chronic inflammation, such as 
rheumatoid arthritis (RA) is unknown. RA is known to compromise female 
fertility, and often affects women in their fertile age. Serum anti-Müllerian 
hormone (AMH) levels are a proxy for the total number of primordial follicles, 
and a reliable predictor of the age at menopause. Our objective was to study 
the longitudinal intra-individual decline of serum AMH levels in female RA 
patients.
Methods: Female RA patients from a nationwide prospective cohort (PARA 
study, 2002-2008), were re-assessed in 2015-2016. Serum AMH levels were 
measured using the picoAMH assay and compared to healthy controls. A 
linear mixed model (LMM) was built to assess the effect of RA-related clinical 
factors on the decline of serum AMH levels. 
Results: One hundred and twenty-eight women were re-assessed at an age of 
42.6 ± 4.4 years, with a median disease duration of 15.8 (IQR 12.7 – 21.5) years. 
The time between the first and last AMH assessments was 10.7 ± 1.8 (range 6.4 
– 13.7) years. Participants represented a more fertile selection of the original 
PARA cohort. At follow-up, 39% of patients had AMH levels below the 10th 
percentile of controls (95%CI 31 – 48%), compared to baseline levels (16%; 
95%CI 9.3 – 22%). The LMM showed a significant decline of AMH levels with 
increasing age, but no significant effect of RA-related factors on AMH.
Conclusion: AMH levels in RA patients showed a more pronounced decline 
over time than expected, supporting the idea that also in chronic inflammatory 
conditions, reproductive function is compromised, resulting in a faster decline 
of ovarian function over time and probably an earlier age at menopause. 
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The ovarian function depends on both the quantity as well as the quality of the 
primordial follicles in the ovaries. At birth, there are approximately 1,000,000 
primordial follicles present in the ovaries. This number gradually decreases over time, 
resulting in about 300,000 remaining follicles at menarche.1,2 During her twenties 
and thirties, a woman's follicle pool further decreases, with a slight acceleration in 
her late thirties and early forties. Finally, the near depletion of the ovarian follicle pool 
is marked by the cessation of menstruation.3 The last menstrual period in a woman's 
life span, i.e. the menopause, occurs at a mean age of 51 years. Infertility generally 
sets in approximately 10 years before a woman experiences menopause.3 This results 
not only from the decline in number of developing ovarian follicles over time, but 
also from a decrease in quality of the oocytes maturing within these follicles due to 
accumulated damage from birth onwards.4 
The age at which a woman reaches menopause, as well as the preceding period of 
decreased fertility and infertility, varies greatly between women.3 At present, the 
serum level of anti-Müllerian hormone (AMH) is the most reliable predictor for the 
age at which a woman will enter menopause.5 Although, prediction of the actual 
age at menopause based on a single AMH measurement is still not very precise.5 
AMH is a member of the transforming growth factor β family and is produced in the 
ovary by granulosa cells of early developing follicles.6 In both healthy and subfertile 
women, there is a strong correlation between serum AMH levels and the number of 
developing follicles in the ovaries. It has been shown that serum AMH levels become 
undetectable approximately 5 years before a woman reaches menopause.7 
Genes associated with the age of menopause,  and more specifi cally the length 
of the reproductive life span of a woman, are generally involved in DNA repair 
and maintenance as well as in the immune system.8 In this way, genes involved in 
healthy ageing are also predictors for ovarian function. Indeed, a compromised 
ovarian function has been described in patients with type II diabetes mellitus9 and 
in young girls with cancer.10 This suggests that an unhealthy soma results in an early 
decline of ovarian function. It is unknown whether the same holds true for chronic 
inflammation.8 
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Rheumatoid arthritis (RA) is an example of a chronic inflammatory auto-immune 
disease that often affects women in their fertile age. RA not only affects the joints, 
but can also cause extra-articular damage, affecting different organ systems.11,12 
A prolonged time to pregnancy13,14 and a younger age at which menopause sets in15,16 
are both indicators that in women with RA the ovarian function may be compromised 
as well. 
In women with RA, AMH levels at time of diagnosis have been found to be comparable 
to those in healthy controls.17 Furthermore, after 6 months of methotrexate (MTX) 
therapy in RA patients, AMH levels did not differ from those in patients who did not use 
MTX.17 When analysing women with established RA, AMH levels were indeed lower 
compared to healthy controls.18,19 However, thus far there have been no longitudinal 
studies on AMH levels in RA patients. Nor has the effect of disease characteristics on 
the decline of AMH levels over time been studied.  
The objective of the current study was to investigate the intra-individual change in 
AMH levels over a longer time period in women with RA. We compared serum AMH 
levels in RA patients with those in controls from the general population, and studied 




For this observational cohort study, patients were recruited who had participated 
in the Pregnancy-induced amelioration of RA (PARA) study. The PARA study was a 
nationwide prospective cohort study, which was performed in the Netherlands in 
2002-2010.20 Patients were invited to participate by their attending rheumatologist 
if they had a diagnosis of RA according to the 1987 ACR criteria,21 and if they were 
actively trying to conceive or were already pregnant. Patients had to have a good 
understanding of the Dutch language.20 Patients could participate in the PARA study 
more than once. For the current follow-up study, patients were contacted when they 
had given consent to be contacted for future research, and when they had at least 
1 non-pregnant serum sample available (i.e. from a preconception visit, or from a visit 
6 months postpartum).
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The majority of the PARA subjects had been contacted in 2013-2014 for a questionnaire 
on fertility.22 As a result, addresses were up to date whenever possible. Patients 
currently living outside of the Netherlands or Belgium were excluded.
Ethical approval
The original PARA study, as well as the current follow-up study, were performed 
according to the Declaration of Helsinki, and were approved by the Medical Ethics 
Review Committee of the Erasmus MC. 
Data collection
During the original PARA study,20 patients were visited at their homes before, during, 
and after pregnancy, with the fi nal visit 6 months postpartum. Each assessment 
consisted of a questionnaire driven interview on disease characteristics and use of 
medication, measurement of disease activity, and drawing of serum samples. 
For the current study, patients received an information letter, and thereafter were 
contacted by telephone. Patients who gave informed consent, were visited at their 
home address for blood sampling, and they completed an online questionnaire 
including questions on menstrual cycle, age at menarche, hormone use, and other 
possible iatrogenic causes for amenorrhoea.
Measurements
Disease activity was measured during the PARA study visits using the Disease Activity 
Score assessing 28 joints (DAS28) for tenderness and swollenness, combined with 
serum C-reactive protein (CRP) levels.23
Serum samples were stored at -80ºC. Serum AMH levels were measured in the 
samples from all preconception and 6 month postpartum PARA study assessments, 
as well as in the newly acquired samples from the follow-up visit. 
AMH values were measured using the picoAMH assay, provided by Ansh labs 
(Houston, Texas, USA).24,25 Inter and intra assay coeffi cients of variation were both < 
5%. 
Controls
Serum AMH levels in patients were compared to a group of healthy controls. This 
international reference cohort existed of 554 healthy adult women, aged 18-47 years, 
who had a regular menstrual cycle and/or were proven fertile.26 AMH levels in controls 
were originally reported as measured by the Beckman Coulter Gen II Assay. Therefore, 
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a conversion factor was used to compare AMH levels in the patient group to those in 
the controls:25  
AMH (picoAMH assay in ng/mL) = (1.45 * AMHGen II) + 0.32 
Statistical analysis
Values are presented as mean ± SD for normally distributed variables, as median 
(IQR) if values were non-normally distributed, and as number (%) for dichotomous 
variables. The number of missing values are given for each variable. 
To approach a normal distribution, AMH levels were log-transformed for analysis. To 
correct for different distribution of ages between patients and controls at the different 
time points, AMH levels were compared to controls using analysis of covariance 
(ANCOVA) on log-transformed AMH levels with adjustment for age.
Sensitivity analyses were performed by excluding women using combined oral 
contraceptives, and by excluding women using any steroid sex hormones. 
To reduce potential bias in the longitudinal analysis due to missing values, multiple 
imputation was performed. To incorporate the longitudinal outcome into the 
imputation procedure, a preliminary linear mixed model (LMM) with a random 
intercept and random slope was fitted, using only completely observed covariates, 
and age as time variable. The random intercept and slope estimated by this model 
were considered a summary of the outcome, and were added as  predictor variables to 
the imputation models.27
To study the effect of RA-related factors (disease duration, presence of ACPA, presence 
of RF, presence of erosions, past use of MTX) on the AMH levels, a LMM with random 
intercept and slope was built, using biological age as time variable. To obtain a 
more normal distribution of residuals and random effects in the LMM, a square root 
transformation was applied to the AMH levels. Interactions between ACPA, RF, and 
erosions, and between age and disease duration, were considered in the model. 
Pooled results from the 10 multiple imputed datasets are presented.
Since gynaecological age (i.e. years since menarche) may more precisely explain the 
inter-individual difference than biological age, a second analysis was performed 
using gynaecological age as time variable. 
Statistical analysis was performed using Stata SE v14 (College Station, Texas, USA) 
and R version 3.3.1 (2016, the R foundation for statistical computing; packages used: 
mice, lme4). 
48760 Jenny Brouwer.indd   106 20-12-17   09:44





Serum samples for 128 patients (43% of the original PARA cohort) were available for 
analysis. (Figure 1) For 2 patients no questionnaire data were available for the latest 
visit, but they were included in the analyses.  Baseline characteristics are given in 
Table 1. 
Figure 1 – Flow chart showing the patients from the original PARA study that did participate in the current study 
and were available for analysis
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Table 1 – Characteristics of women with rheumatoid arthritis who participated in the PARA study and had a 
follow-up assessment in 2015/2016 (N=128)
Variables     Variables  
Age (years) Anti-rheumatic drugs at follow-up
at first visit 31.8 ± 3.8 Methotrexate 65 (51%)
at follow-up 42.6 ± 4.4 Prednisone 16 (13%)
Sulfasalazine 15 (12%)
Age at menarche (years) 13.1 ± 1.4 Hydroxychloroquine 17 (13%)
missing 9 (7.0%) Leflunomide 5 (3.9%)
Smokers at first visit 9 (7.0%) Biologicals - total n (%) 71 (55%)
missing 2 (1.6%) Etanercept 29 (23%)
Infliximab -
Disease characteristics Certolizumab 2 (1.6%)
Duration of disease (years) Adalimumab 20 (16%)
at first visit 4.8 (2.1-10.4) Golimumab 3 (2.3%)
at follow-up 15.8 (12.7-21.5) Abatacept 6 (4.7%)
  Missing 1 (0.8%) Rituximab 2 (1.6%)
Presence of ACPA, n (%) 78 (61%) Tocilizumab 9 (7.0%)
Presence of RF, n (%) 85 (66%)
Presence of erosions, n (%) 77 (60%) Use of methotrexate
missing 3 (2.3%) Ever used MTX 113 (88%)
missing 2 (1.6%)
Hormone use at follow-up Cumulative duration of MTX use
None 62 (48%) never used 13 (10%)
Oral contraceptive pill 25 (20%) less than 1 year 12 (9.3%)
Levonorgestrel releasing IUD 37 (29%) 1 to 5 years 27 (21%)
Injectable progesterone 2 (1.6%) 5 to 10 years 31 (24%)
missing 2 (1.6%) > 10 years 25 (20%)
missing 20 (16%)
Cumulative years MTX in users 5.8 (2.2-10.2)
RA = rheumatoid arthritis ; ACPA = anti-citrullinated protein antibodies ; RF = rheumatoid factor ; IUD = intra-uterine 
device ; MTX = methotrexate
We compared the 128 study participants to the non-participating subjects (n=167) of 
the former PARA cohort (Table 2). There was a significant lower percentage of smokers 
among participants (7%) than in the non-participants (17%) (p=0.013). Furthermore, 
nulliparity was significantly more common among the non-participants (22%) than 
in the participants (4.7%) at the end of their final PARA episode (p<0.001). There were 
no significant differences in age, number of episodes participated in the PARA study, 
disease duration during the PARA study or current disease duration, presence of ACPA 
or RF, preconceptional disease activity during last PARA episode, or disease activity at 
the last PARA visit (either preconceptional or 6 months postpartum). 
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Of the participants, 41 (32%) women reported amenorrhoea (i.e. no menstruation in 
the preceding 12 months). In 29 women this could be explained by continuous oral 
contraceptive use (n=3) or the presence of a hormonal intra-uterine device (n=26), and 
1 woman had a lactational amenorrhoea. Seven women had had a hysterectomy. In 
4 women (3.1%) the amenorrhoea could not be explained by other causes, and they 
were considered postmenopausal. Their menopause had been at an age of 39, 44, 
44 and 45 years respectively. Three of them had AMH values below the LoD, and in 1 
patient the serum AMH level was 0.0114 ug/L. 
Table 2 - Comparison of participants and non-participants in the follow-up of the PARA study 
  Current study Non-participants  
P value
 Number of unique patients n=128 n=167
Age¶ - years 42.5 ± 4.4 43.4 ± 4.1 0.055§
Age at last PARA episode - years 32.0 ± 3.9 32.8 ± 3.9 0.11§
Smoker during PARA study 9 (7%) 28 (17%) 0.013†
missing 2 (2%) 4 (2%)
Number of episodes within PARA study
1 episode 98 (77%) 139 (83%)
2 episodes 24 (19%) 24 (14%)
3 episodes 6 (5%) 3 (2%)
4 episodes - 1 (1%)
Obstetric history
Never pregnant before PARA study 73 (57%) 93 (56%) 0.91†
Pregnant during last PARA episode 117 (91%) 120 (72%) <0.001†
Nulliparous at end of PARA study 6 (4.7%) 36 (22%) <0.001†
Disease Characteristics
Duration of RA¶ - years 15.6 (12.6 - 20.9) 15.5 (13.1 - 20.5) 0.88‡
missing - 2 (1%)
Duration of RA at fi rst PARA episode 4.2 (2.0 - 9.6) 4.7 (1.9 - 8.5) 0.99‡
missing - 2 (1%)
Presence of ACPA 78 (61%) 112 (67%) 0.33†
Presence of RF 86 (67%) 125 (75%) 0.16†
Presence of erosions 77 (60%) 100 (60%) 0.61†
missing 3 (2.3%) 9 (6.4%)
Disease activity Score (DAS28) during last PARA episode
Preconception 3.6 ± 1.3 3.8 ± 1.2 0.17§
missing 51(40%) 54 (32%)
First trimester 3.5 ± 1.2 3.6 ± 1.2 0.57§
missing 37 (29%) 70 (42%)
last available DAS28 (non-pregnant) 3.5 ± 1.2 3.5 ± 1.2 0.79§
missing - 4 (2%)
† Fisher's exact test; ‡ Mann-Whitney U test; § Student's t test
¶ at January 1st 2016




Serum AMH levels during follow-up were compared to AMH levels in healthy controls 
(figure 2). The mean age in controls was 30.6 ± 7.4 years, with a range of 18.0 – 46.8 
years. The age range for patients at the follow-up visit was 31.6 – 53.5 years. Corrected 
for age, AMH levels in women with RA at the follow-up visit were significantly lower 
than those in controls (p<0.001). 
Figure 2 – First and last available serum anti-Müllerian hormone (AMH) levels (ug/L) in women with rheumatoid 
arthritis who participated in the Pregnancy-induced Amelioration of Rheumatoid Arthritis (PARA) study and 
were visited again after 6.4 – 13.7 years. The lines represent the 10th, 50th and 90th percentiles of AMH values in 
healthy controls (Lie Fong 2012)26 
Looking at the age specific percentiles, 50 subjects (39%; 95%CI 31–48%) had a 
serum AMH level below the 10th percentile, compared to 20 patients (16%; 95%CI 
9.3–22%) at the first available assessment (figure 2). At the follow-up assessment, 3 
RA patients were older than 51 years, and as such, their age exceeded the age range of 
the nomogram (maximum age 51 years). 
In patients not using oral contraceptives (n=100), the percentage of women with 
AMH levels below the 10th percentile was 36% (95%CI: 27–45%). In women not using 
any steroid sex hormones (n=61), this was 33% (95%CI 21–47%). 
In Table 3 the age-specific AMH percentiles are shown for all subjects at the first 
and last measurement, grouped by disease characteristics. At the last assessment, 
higher percentages of patients with AMH levels below the 10th percentile were seen 
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in ACPA positive patients versus ACPA negative patients, in RF positive patients versus 
RF negative patients, and in patients with erosions at baseline versus those without 
erosions at baseline. However, these differences were not statistically signifi cant. 
Table 3 – Distribution of age-specifi c percentiles of serum AMH levels in women with rheumatoid arthritis from 




neg Pos neg pos no Yes
(n=50) (n=78) (n=43) (n=85) (n=48) (n=77)
First AMH measurement
<P10 7 (14%) 13 (17%) 5 (12%) 15 (18%) 5 (10%) 15 (19%)
P10-P50 18 (36%) 31 (40%) 14 (33%) 35 (41%) 17 (35%) 32 (42%)
P50-P90 22 (44%) 30 (38%) 21 (49%) 31 (36%) 24 (50%) 26 (34%)
>P90 3 (6.0%) 4 (5.1%) 3 (7.0%) 4 (4.7%) 2 (4.2%) 4 (5.2%)
Last AMH measurement
<P10 15 (30%) 35 (45%) 12 (28%) 38 (45%) 15 (31%) 34 (44%)
P10-P50 10 (20%) 17 (22%) 6 (14%) 21 (25%) 11 (23%) 16 (21%)
P50-P90 23 (46%) 20 (26%) 20 (47%) 23 (27%) 21 (44%) 20 (26%)
>P90 1 (2.0%) 4 (5.1%) 2 (4.7%) 3 (3.5%) 1 (2.1%) 4 (5.2%)
NA 1 (2.0%) 2 (2.6%)   3 (7.0%) -   - 3 (3.9%)
Values are given as n(%)
ACPA = anti-citrullinated protein antibodies, RF = rheumatoid factor, AMH = anti-Müllerian hormone
$ at baseline
¶ the presence or absence of erosions were missing for n=3 subjects
Linear mixed model
For 1 patient 8 measurements were available, 4 patients had 7 measurements, 
1 patient had 6 measurements, 13 patients had 5 measurements, 50 patients had 
4 measurements, 15 patients had 3 measurements, and 44 patients had 
2 measurements. The intra-individual mean time between the fi rst available AMH 
measurement and the last was 10.7 ± 1.8 years, with a range of 6.4 – 13.7 years. 
The mean age at the fi rst AMH measurement was 31.8 ± 3.8 years, and at the fi nal 
assessment 42.6 ± 4.4 years. 
Repeated measurement analysis using a LMM showed a signifi cant decrease of serum 
AMH levels with increasing age. None of the RA-related variables (disease duration, 
presence of ACPA, of RF, or of erosions, MTX use (ever)) did have a signifi cant effect on 
the AMH levels over time in this group of 128 female RA patients (Table 4). Comparing 
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the full model shown in table 4 with a simple model of AMH based on age alone 
using a likelihood ratio test, did not reveal any significant differences, confirming the 
findings in table 4.
Table 4 - estimates of linear mixed model describing the change of serum anti-Müllerian hormone (AMH) levels 
(applying square root transformation) with increasing age in 128 female RA patients 
Variable Estimate Standard error 95% Confidence interval
(Intercept)                            4.648 0.350 3.962 - 5.334
Biological age - per year $ -0.077 0.007 -0.090 - -0.063 ǂ
Disease duration ƚ 0.015 0.031 -0.046 - 0.076
Presence of ACPA ƚ -0.544 0.349 -1.227 - 0.140
Presence of Erosions  ƚ -0.076 0.239 -0.545 - 0.393
Presence of RF  ƚ -0.312 0.281 -0.863 - 0.239
Ever used MTX 0.005 0.187 -0.361 - 0.372
Age * Disease duration -0.001 0.001 -0.002 - 0.001
ACPA * Erosions 0.364 0.447 -0.512 - 1.239
ACPA * RF 0.413 0.441 -0.451 - 1.276
Erosions * RF -0.146 0.390 -0.910 - 0.618
ACPA* Erosions * RF -0.121 0.573 -1.243 - 1.001  
ACPA = anti-citrullinated protein antibodies ; RF = rheumatoid factor ; MTX = methotrexate
$ age is used as time variable in the model
ƚ variable at baseline
ǂ p<0.05
The additional analysis with gynaecological age as time variable, was performed in 
the 122 patients that reported their age at menarche. Besides the decline of AMH with 
increasing gynaecological age, no other variables did show a significant effect. The 
full model based on gynaecological age was not significantly different from a simple 
model of AMH based on gynaecological age exclusively.
DISCUSSION
Women with RA had a compromised ovarian function compared to healthy controls, 
with a considerably larger proportion of women with RA having AMH levels below the 
age-specific 10th percentile. Assessment of serum AMH levels over time in female RA 
patients revealed that levels decreased more rapidly in patients compared to controls. 
Longitudinal analyses did not show any significant effect of RA-related factors on 
serum AMH levels.
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The more rapid decline of serum AMH levels over time in women with established RA 
indicates that chronic inflammation compromises ovarian function. The latter may 
even decline faster than was currently found in women with RA since the participants 
in this study represented a more fertile selection, with also less smokers, than the 
original PARA cohort. Since the original PARA cohort was already a relative healthy 
cohort,20 the true difference between women with RA and the general population 
may be even larger. 
The compromised ovarian function in RA may be a direct effect of cumulative 
inflammatory damage to the ovaries. Although we found no signifi cant association 
between disease activity and AMH levels in current or previous analyses, there is a 
relation with ACPA-positivity, which represents patients with on average more active 
disease, often requiring a more intensive treatment strategy.28 We have previously 
reported signifi cantly lower serum AMH levels in ACPA-positive patients,19 and in the 
current study more ACPA-positive than ACPA-negative patients appeared to have AMH 
levels below the 10th percentile. Furthermore, in the linear mixed model, the negative 
association of ACPA-positivity with serum AMH levels was present, although non-
signifi cant, which may have been due to the lower number of subjects in this study. 
The present idea among rheumatologists is that ACPA positive RA may be a different 
disease than ACPA negative RA. It is not clear whether the reduced ovarian function is 
a result of this probably different disease mechanism, or of increased inflammatory 
damage due to longer periods of high disease activity. However, the lower AMH levels 
in patients who are ACPA-positive, fi t with the overall concept that ACPA-positive RA 
is a more destructive disease with more extra-articular manifestations.28
Otherwise, there may be a genetic basis for the compromised ovarian function in RA. 
In genome-wide association studies (GWAS), not only genes linked to DNA repair and 
genome maintenance have been related to age at menopause, but also genes linked 
to immune response seem to determine the timing of menopause.8  Whether RA and 
early menopause share a common genetic basis, may be the focus of future research. 
Regarding generalizability, we should consider the recent changes in diagnosis and 
treatment of RA. Where patients from the PARA cohort were classifi ed as having RA 
according to the 1987 ACR criteria,21 nowadays RA is often recognized and diagnosed 
at an earlier stage, when less damage has been done.29 Furthermore, new treatment 
guidelines have been developed over the last decade, focusing on early combination 
therapy in a treat-to-target regimen, and the addition of biological disease modifying 
antirheumatic drugs such as tumor necrosis factor (TNF) inhibitors for a tighter disease 
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management.30 The next generation of young female RA patients may therefore have 
a milder course of the disease, with better long-term outcomes. Whether ovarian 
function and reproductive performance will also benefit from these changes, should 
be addressed in future studies. 
Fifty percent of the current participants used hormonal contraceptives during the 
follow-up assessment, mainly progesterone releasing intra-uterine devices, or the oral 
contraceptive pill (OCP). The effect of exogenous steroid hormones on serum AMH 
levels is still unclear, with several studies reporting no significant effect of exogenous 
hormones on serum AMH levels, whereas other studies have shown, although subtle, 
lower AMH levels in users of either OCPs or progesterone only pills.31,32 Sensitivity 
analyses excluding women using any of these hormones, still showed one-third of 
patients having AMH levels below the 10th percentile at follow-up. Therefore, the 
current use of contraceptives could not explain the decreased long-term serum AMH 
levels in our study group.
AMH levels in this study were measured with an ultrasensitive picoAMH assay. The 
comparison of AMH levels between patients and controls should be considered with 
caution, since the conversion factor applied to the controls has been developed in 
another laboratory than the laboratory that performed the measurements with the 
new assay. Inaccuracy due to the conversion, may give deviating results.25 Furthermore, 
the currently applied picoAMH assay has a lower limit of detection compared to the 
Gen II assay that was used for the AMH measurements in controls. Nevertheless, 
adjusting the very low values in the current patients to the LoD applied in the controls, 
still resulted in a significantly higher percentage of patients with AMH values below 
the 10th percentile of controls.
In conclusion, serum AMH levels show a faster decline over time in women with RA 
compared to healthy controls, supporting the idea that in chronic inflammatory 
conditions, the body is less fit for reproduction. Optimal treatment of chronic 
inflammatory disease in an early phase may improve long-term women's health.
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This thesis illustrates the need for individualized decision making and a 
multidisciplinary approach in fertility care for patients with rheumatoid arthritis. 
Moreover, it provides some useful new insights into fertility, having distinct 
implications for both rheumatologists as well as for gynaecologists.
Implications for rheumatologists
In young women with rheumatoid arthritis who desire to build a family, for years the 
policy among rheumatologists has been to limit the prescription of antirheumatic 
drugs. Fear of possible teratogenic effects withheld intensive treatment in women 
during the preconception period. 
Nowadays, attention for preconception care in patients with RA is gradually 
increasing among rheumatologists. In 2016, a EULAR task force has reported 
considerations on antirheumatic treatment in women before, during and after 
pregnancy.1 However, concerns on preconception treatment are mainly limited to 
drug safety for the foetus during pregnancy and breastfeeding, whereas the effects 
on fertility are only briefly addressed.
This thesis has shown, that during the preconception period, antirheumatic 
treatment should be maintained, or adjusted in case teratogenic drugs are part of a 
patient's current treatment. Active disease should be treated intensively during the 
preconception period, both to reduce the negative effect of disease activity on the time 
to pregnancy, as well as to avoid the use of NSAIDs and high dosages of prednisone 
and their negative effect on fertility. 
Developing adjusted treat-to-target guidelines for the preconception period can 
guide rheumatologists in effectively treating patients and minimalizing risks for 
pregnancy and offspring. Regarding fertility, treatment targets should preferably 
aim for disease remission to reduce time to pregnancy, with avoidance of the use 
of NSAIDs and high dosages of prednisone. The largest benefi cial effect on time to 
pregnancy is to be expected in women with high disease activity, but patients with 
intermediate and low disease activity will also benefi t. Previous studies on pregnancy 
and offspring in women with RA have already shown the importance of treating 
patients with active disease when they are planning a family. An increased maternal 
disease activity during pregnancy has been associated with lower birth weight2 and 
rapid postnatal catch-up growth in the offspring, which in turn is associated with a 
higher risk for cardiovascular and metabolic disease in later life.3 Furthermore, high 
and intermediate disease activity have both been associated with a higher occurrence 
of caesarian sections.2 This thesis emphasizes the need for treatment adjustment 
early in the process of family planning. 
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Fertility care in a woman with rheumatoid arthritis is preferably started as soon as 
she is diagnosed. In all women of fertile age, rheumatologists should discuss family 
planning in an early stage. Patients should be made aware that their ovarian function 
may decline more rapidly compared to healthy women, especially when they are 
ACPA positive. In the light of the general tendency to postpone pregnancy beyond 
age 30 in Western countries, patients with ACPA positive disease especially should 
not delay trying to conceive. Whether the presence of ACPAs in serum by itself is 
responsible for the reduced ovarian function, or the more active disease associated 
with ACPA positivity4 causes damage to the ovary in the long run, remains unclear. 
Follow-up of current early arthritis cohorts with implemented strict treat-to-target 
antirheumatic therapy, could clarify whether tight disease control has a protective 
effect on the ovarian function.
Besides general lifestyle recommendations regarding fertility, such as cessation of 
smoking, body weight reduction in obese patients, and the use of folic acid, sexual 
functioning should be a recurrent topic. The help of a sexologist should be offered 
when patients experience problems in this area. 
Early consultation of a gynaecologist or endocrinologist to exclude other issues 
regarding fertility in the patient or her partner may prevent unnecessary delay of 
conception. 
Implications for gynaecologists
Gynaecologists and fertility specialists attending patients with RA should be aware of 
the possible effects of the disease, its manifestations, and antirheumatic treatment 
on both fertility, as well as on different treatments. When active disease is present, 
it may be worthwhile to postpone fertility treatment until antirheumatic treatment 
has been optimized and resulted in less active disease or preferably remission, and 
the patient does not require regular NSAIDs use or high dosages of prednisone. 
The increased chance of spontaneous conception when the disease is more strictly 
controlled, should be considered and discussed with patients, thus avoiding possibly 
unnecessary fertility treatments.
The distinction between different rheumatic diseases should be made. Many 
rheumatic conditions are known, but in only a few the effect on fertility has been 
documented. This thesis demonstrates a reduced fertility and a decline in ovarian 
function in women with RA. However, in patients with systemic lupus erythematosus 
(SLE), fertility is not compromised, although miscarriages and pregnancy 
complications are more frequent, resulting in smaller family sizes in women with SLE.5 




Studies on ovarian function in SLE show conflicting results.6,7 In Sjögren's disease, no 
reduced fertility has been reported,8,9 but lower AMH levels have been found.10 Since 
the spectrum of rheumatic diseases is broad, collaboration between gynaecologists 
and rheumatologists is an essential part of preconception care in women with 
rheumatic diseases. Not only should the effect and safety of medical treatment in the 
preconception period be considered, but also the timing of fertility treatments. This 
will optimize the chance of a successful outcome.
Not only in patients with rheumatic diseases, but in all patients visiting a reproductive 
medicine unit, comorbidities and medication use should be considered as possible 
fertility compromising factors. Current guidelines on fertility assessments, such as 
the national guideline on fertility assessments of the Dutch Society of Obstetrics 
and Gynaecology (NVOG), and the guideline on ‘Fertility Problems: Assessment and 
Treatment’ by the National Institute for Health and Care Excellence (NICE) do mention 
possible effects of prescription and over-the-counter drugs on conception and 
pregnancy. However, comorbidity is only mentioned in the context of possible tubal 
occlusion and anovulation. Guidelines should also mention the possibility of direct 
interaction of comorbidity and fertility. For a patient with comorbidity, consultation 
of attending physicians on the effects of the condition on fertility and vice versa, and 
on possible treatment adjustments, as well as discussing timing of the start of fertility 
treatments, may both increase the chance of a positive outcome of fertility treatment 
as well as favour maternal health. 
Suggestions for future research
The studies in this thesis have revealed several associations of rheumatoid arthritis 
and antirheumatic drugs with subfertility or a prolonged time to pregnancy. 
Prospective studies in women with RA who will start planning a family, may elucidate 
whether a strict control of the disease, and avoidance of preconception use of NSAIDs 
and high dosages of prednisone will result in less subfertility in this patient group. 
However, the effect of earlier diagnosis since the introduction of the ACR/EULAR 2010 
classifi cation criteria for rheumatoid arthritis,11 and of the current treat-to-target 
guidelines, including use of biologic DMARDs12 should be taken into consideration.  
Active disease as well as the use of NSAIDs in women with RA, are associated with 
a longer time to pregnancy and subfertility. Hence, pain as a manifestation of active 
disease may be an underlying cause for a longer time to pregnancy, causing problems 
in sexual intercourse, or a reduced intercourse frequency. Since the studies in this thesis 
were post-hoc analyses of the PARA study, no information was available on intercourse 
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frequency and timing of intercourse during the menstrual cycle. Prospective studies 
in women with RA, documenting menstrual cycles and intercourse frequencies, along 
with pain scores and the use of antirheumatic drugs, may provide insight in the effect 
of pain and antirheumatic medication on sexual intercourse. 
The mechanism behind subfertility in active disease may be subject of future research. 
Although the implantation rate after IVF or ICSI treatments in RA patients was high 
(chapter 3), the number of patients was low, and possible selection bias was present. 
Therefore, the possibility of failure of embryo implantation as underlying cause for 
subfertility should be considered. Many growth factors and cytokines are involved in 
the embryo-endometrium interaction.13 Serum cytokine levels have been shown to 
be altered in RA patients. Exploratory studies on the association of serum cytokine 
levels in RA with subfertility or time to pregnancy may point towards cytokines of 
interest. Whether the intrauterine environment also suffers from this imbalance, 
might be studied subsequently by proteome studies in aspirated endometrial 
fluid. Identification of fertility impairing cytokines in the future may even indicate 
treatment targets in this specific patient group. 
Regarding ovarian function, long term studies of serum AMH levels at different time 
points in existing cohorts of women with established RA, and studies in early arthritis 
cohorts, may provide information on the actual age at menopause. Studies on serum 
AMH levels in women receiving the current more intensive treatment strategies, 
can reveal whether early diagnosis and start of treatment, current treat-to-target 
guidelines, and treatment with biological DMARDs have a protective effect on ovarian 
function. AMH recovery has been described in childhood cancer survivors, in whom 
decreased AMH levels are found as well at diagnosis as shortly after chemotherapy. 
Future studies of serum AMH levels in RA, should reveal whether intensive treat-to-
target antirheumatic treatment may lead to recovery of ovarian function in young 
women with RA.
Conclusion
The results in this thesis emphasize the need for personalized medicine in fertility 
care. Current national and international guidelines, both in rheumatology, as well as in 
reproductive medicine, should take into account the interaction between comorbidity 
and fertility. For patients with RA, but also for patients with other comorbidities, when 
planning a family, a multidisciplinary approach may limit the time to pregnancy and 
favour maternal health. 
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Rheumatoid arthritis (RA) is one of the most common rheumatic diseases. Impaired 
fertility in women with RA has been reported, but little is known about the exact 
mechanisms behind subfertility in this patient group. The aims of this thesis were (I) 
to assess the time to pregnancy in a cohort of women with RA who wished to conceive, 
and to determine its association with clinical aspects of RA, (II) to study the occurrence 
of miscarriages in RA, and (III) to research the ovarian function in RA, both during the 
preconception period, as well as (IV) during a longer time period.  
The introduction in chapter 1 gives a general overview of RA, its diagnosis and 
treatment. Furthermore, a description of ovarian function, and the use of anti-
Müllerian hormone (AMH) as a serum marker for this ovarian function is given. After 
a brief explanation on subfertility in the general population, an overview is given on 
what is known about fertility problems, miscarriages, and menopause in women with 
RA. Finally, the design of the Pregnancy Induced Amelioration of RA (PARA) study is 
described, since the studies in this thesis were performed mainly within the PARA 
cohort.
Chapter 2 describes the increased time to pregnancy (TTP) within the PARA cohort 
and its relation with several disease characteristics and anti-rheumatic treatment. A 
longer TTP was related to age, nulliparity, disease activity (DAS28), and preconception 
use of non-steroidal anti-inflammatory drugs (NSAIDs) and prednisone. The effect 
of prednisone was dose-dependent, with a longer TTP when higher dosages of 
prednisone were taken.
The outcomes of fertility assessments in RA patients are addressed in chapter 3. After 
fertility work-up, subfertile women with RA often received a diagnosis of unexplained 
subfertility, or of anovulation. Unexplained subfertility was related to periconception 
use of NSAIDs, suggesting that these drugs have a negative effect on fertility. A relative 
high percentage of pregnancies were the result of fertility treatments. Despite the 
higher incidence of subfertility in the study group, the outcome of fertility treatments 
appeared favorable.
In chapter 4, the association between miscarriages and RA related clinical factors 
is studied. The miscarriage rate in the PARA cohort was comparable to that in the 
general population. There was a possible association of the occurrence of miscarriages 
with ACPA positive disease, but this was not statistically signifi cant. The majority of 
patients who had miscarried and continued trying to conceive, achieved an ongoing, 
successful pregnancy within one year after their miscarriage.
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The ovarian function in early RA is evaluated in chapter 5. Serum AMH levels 
in women within the Rotterdam Early Arthritis Cohort who had recently been 
diagnosed with RA were not different from AMH levels in healthy controls. There was 
no association of AMH levels with RA serology, the presence of erosions, or disease 
activity. Furthermore, six months of methotrexate therapy did not result in a faster 
decline of serum AMH levels. 
Chapter 6 returns to the PARA cohort, studying the ovarian function in the 
preconception period and its relation with time to pregnancy. In this group of 
women with a median disease duration of RA of 4.5 years, serum AMH levels were 
significantly lower than in healthy controls, with 17% of patients below the age-
specific 10th percentile of healthy controls. Serum AMH levels were lower in ACPA 
positive patients. Time to pregnancy was not associated with AMH levels. 
The decline of ovarian function in RA over a longer period is studied in chapter 7. For 
this purpose a follow-up study of the women participating in the PARA-cohort was 
undertaken, with last serum samples being taken at a median disease duration of 15.8 
years. Over the years, serum AMH levels in women with RA showed a steeper decline 
than healthy controls with 39% of women having serum AMH levels below the 10th 
percentile of healthy controls at the last observation. 
Finally, in the general discussion in chapter 8 clinical implications for both 
rheumatologists and gynaecologists are described, and suggestions for future 
research are given. The importance of individualized medicine in women with 
rheumatoid arthritis is discussed. 
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Reumatoïde artritis (RA) is een van de meest voorkomende reumatische aandoeningen. 
Uit eerdere onderzoeken blijkt dat vrouwen met RA verminderd vruchtbaar zijn, 
maar welk mechanisme hieraan ten grondslag ligt is niet bekend. Dit proefschrift had 
als doel het bestuderen van (I) de duur tot het tot stand komen van een zwangerschap 
bij vrouwen met RA en het verband daarvan met ziektegerelateerde factoren, (II) het 
optreden van miskramen bij vrouwen met RA, (III) de ovariële functie van vrouwen 
met RA in de preconceptionele periode en (IV) de ovariële functie op de lange termijn. 
De inleiding in hoofdstuk 1 geeft een algemeen overzicht van de ziekte RA, de 
diagnostiek, en de behandeling. Vervolgens wordt uitleg gegeven over de ovariële 
functie en het gebruik van anti-Müllers hormoon (AMH) in het serum als indicatie 
voor deze ovariële functie. Na een korte toelichting over subfertiliteit in de algemene 
bevolking, wordt beschreven wat al bekend is over vruchtbaarheid, miskramen en 
menopause in vrouwen met RA. Tot slot wordt de PARA-studie beschreven, welke de 
basis is geweest voor een groot deel van dit proefschrift. 
Hoofdstuk 2 beschrijft de langere duur tot zwangerschap binnen het PARA-cohort 
en de relatie hiervan met verschillende ziekteaspecten en anti-reumatische therapie. 
Een langere tijd tot zwangerschap was gerelateerd aan leeftijd, nullipariteit, 
ziekteactiviteit en preconceptioneel gebruik van non-steroidale anti-inflammatoire 
middelen (NSAID's) en prednison. Het effect van prednison was dosis-afhankelijk, 
waarbij het langer duurde tot een vrouw zwanger werd wanneer zij een hogere 
dosering prednison gebruikte.
De uitkomsten van vruchtbaarheidsonderzoek bij vrouwen met RA worden beschreven 
in hoofdstuk 3. Na oriënterend fertiliteitsonderzoek kregen vrouwen met RA vaker 
de diagnoses ‘onverklaarde subfertiliteit’ en ‘anovulatie’. Vrouwen die voor of rondom 
de conceptie NSAID's gebruikten, waren vaker onverklaard subfertiel, wat suggereert 
dat deze middelen een negatieve invloed hebben op de vruchtbaarheid. Verder was 
een relatief hoog percentage zwangerschappen het resultaat van vruchtbaarheids-
behandelingen. Ondanks het hogere percentage vrouwen met subfertiliteit in de 
studiegroep, lijken de uitkomsten van vruchtbaarheidsbehandelingen gunstig.
In hoofdstuk 4 wordt het verband tussen miskramen en RA-gerelateerde klinische 
factoren onderzocht. Miskramen traden bij de zwangere vrouwen in het PARA-
cohort even vaak op als in de algemene bevolking. Er was mogelijk een relatie tussen 
het optreden van een miskraam en ACPA-positieve ziekte. Het merendeel van de 
patiënten die na een miskraam opnieuw probeerden zwanger te worden, bereikte dit 
binnen een jaar met een levend geboren kind als resultaat.
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De ovariële functie bij vrouwen met recent gediagnostiseerde RA is onderzocht in 
hoofdstuk 5. De serumwaarden van het AMH ten tijde van de diagnose RA verschilden 
niet van die van gezonde controlevrouwen. Er was geen verband tussen de hoogte van 
het AMH en serologie, de aanwezigheid van erosies, of ziekteactiviteit. Ook bleek zes 
maanden behandeling met methotrexaat geen snellere daling van AMH-waarden te 
veroorzaken.
In hoofdstuk 6 wordt in het PARA-cohort de ovariële functie tijdens de periode voor 
de bevruchting bekeken, en de relatie met de tijd tot zwangerschap. Van deze groep 
vrouwen met een mediane ziekteduur van 4.5 jaar had 17% AMH-waardes onder het 
10e percentiel van gezonde controles. Lagere AMH-waarden werden gevonden in 
ACPA-positieve patiënten. De tijd tot zwangerschap had geen verband met de hoogte 
van het AMH.
De afname van de ovariële functie over een langere periode wordt onderzocht in 
hoofdstuk 7. Hiervoor werden vrouwen uit het PARA-cohort opnieuw onderzocht 
bij een mediane ziekteduur van 15.8 jaar. Bij deze vrouwen met RA werd over de 
tijd een sterkere afname van AMH-waarden gezien dan in gezonde controles. Bij de 
laatste observatie, had 39% van de vrouwen met RA een AMH-waarde onder de 10e 
percentiellijn van de gezonde controles. 
Tot slot wordt in de algemene discussie in hoofdstuk 8 besproken welke gevolgen 
de resultaten in dit proefschrift hebben voor de klinische praktijk, zowel voor de 
reumatologen als de gynaecologen. Ook worden suggesties gegeven voor toekomstig 
onderzoek. Het belang van een individuele, patiëntgerichte benadering in de zorg 
voor vrouwen met RA met een kinderwens wordt besproken. 
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ACPA anti-citrullinated protein antibody
ACR American College for Rheumatology
AMH anti-Müllerian hormone
ANCOVA analysis of covariance
anti-CCP anti-cyclic citrullinated peptide
BMI body mass index
CI confi dence interval
COX cyclo-oxigenase
CRP C-reactive protein
DAS disease activity score
DAS28 disease activity score with a 28 joint count
DAS28-CRP DAS28 including CRP
DAS28-CRP-3 DAS28 including CRP and excluding global health measurement
DMARD disease-modifying anti-rheumatic drug
DNA desoxyribonucleic acid
EliA enzyme linked immunoabsorbent assay
ELISA enzyme-linked immunosorbent assay
ESR erythrocyte sedimentation rate
EULAR European League Against Rheumatism
FSH follicle stimulating hormone
FT fertility treatment
GH global health
GWAS genome-wide association studies
HR hazard ratio





IVF in vitro fertilization
LMM linear mixed model
LoD limit of detection
LUF luteinized unruptured follicle
MOH mild ovarian hyperstimulation




NICE National Institute of Health and Care Excellence
NSAID non-steroidal anti-inflammatory drug
NVOG Nederlandse Vereniging voor Obstetrie en Gynaecologie






PARA pregnancy-induced amelioration of rheumatoid arthritis
PI prediction interval
POI premature ovarian insufficiency
RA rheumatoid arthritis
REACH Rotterdam early arthritis cohort
RF rheumatoid factor
SD standard deviation
SLE systemic lupus erythematosus
TGF transforming growth factor
TNF tumor necrosis factor
TTP time to pregnancy
VAS visual analogue scale
WHO World Health Organization
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over het doen van onderzoek naast mijn werk op het Voortplantingscentrum, kwam 
jij direct met het idee om met Mieke om tafel te gaan zitten. Jullie hadden meerdere 
gezamenlijke patiënten en al brainstormend ontstond dit project. Dankzij jouw 
energie, enorme kennis en bodemloze put met ideeën is dit project gaan rollen en 
hebben we iets heel moois kunnen neerzetten. Bedankt dat je dit met mij aandurfde 
en bedankt dat je mij de vrijheid gaf om kliniek, onderzoek en privé steeds te blijven 
combineren.
Geachte dr. Dolhain, beste Radboud, een goede copromotor is onmisbaar in een 
traject als deze. Dankjewel voor al je tijd, wijsheid en hulp in de afgelopen jaren. Ik 
kon altijd bij je langslopen voor overleg, je mening, of om gewoon eens even stoom af 
te blazen. Je enthousiasme werkt aanstekelijk. Bevindingen uit het onderzoek werden 
door jou vaak direct geïllustreerd met patiënten van je spreekuur. Het werkt enorm 
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motiverend om te zien dat je onderzoeksresultaten direct in de kliniek toepasbaar 
zijn. Wat een mooie onderzoekslijn heb je inmiddels opgebouwd met de PARA- en 
PreCARA-studies. Ik vond het een eer om samen met jou dit belangrijke onderwerp 
op de kaart te zetten!  
Op deze plaats wil ik ook graag de leden van de kleine en grote commissie bedanken. 
Geachte professor van der Woude, professor Fauser en professor Kloppenburg: 
bedankt dat u in de kleine commissie heeft willen plaatsnemen. Geachte professor 
Steegers, professor Bijlsma en dr. van der Horst, bedankt voor het plaatsnemen in de 
grote commissie. Geachte dr. Visser, beste Jenny, bedankt voor het plaatsnemen in de 
grote commissie, maar ook voor je brainstormsessies over de ovariële functie in RA en 
je hulp en inzet om de AMH-waardes bepaald te krijgen.
Ook de andere co-auteurs wil ik bedanken. Beste Jits, als co-auteur van het eerste 
artikel heb je me over verschillende hindernissen geholpen. Bedankt voor je tijd en 
geduld hierbij. Rosalie, ‘mijn’ student, bedankt voor je enthousiasme en inzet om van 
zoveel mogelijk patiënten de data compleet te krijgen. Nicole, thank you for helping 
me through the maze of repeated measurement analyses. Your comment filled syntax 
guided me through R. I would not have managed it without you. 
Ook wil ik hier de mensen achter het Reumafonds bedanken. Onderzoek doen kost 
nu eenmaal geld. Dankzij jullie organisatie en de subsidies die jullie elk jaar weer 
beschikbaar stellen, kunnen projecten als deze worden uitgevoerd.
Special thanks to Ansh Labs for providing the pico AMH assays for our studies.
Joyce en Jolanda, als helpende handen van de professoren hebben jullie heel wat 
mailtjes heen en weer gestuurd om de agenda's naast elkaar te leggen voor alle 
overleggen. Tientallen formulieren en abstracts hebben jullie bij hen neergelegd voor 
ondertekening. Bedankt voor jullie hulp!
Ook wil ik al mijn collega's op de afdeling Reumatologie bedanken. Pascal, bedankt 
voor mijn eerste dataset en je hulp bij het ontcijferen. Florentien, jij maakte me 
wegwijs in de PARA-studie, dank je wel. Kamergenootjes en buurtjes van de zesde 
verdieping: Annelieke, Myrthe, Hilal, Martijn, David, Rosaline, Maren, Lonneke, 
Nienke, Kim en Esther: bedankt voor de gezellige lunches, de gezamenlijke NIHES-
colleges, het delen van kamers in Madrid, Trondheim en Rome, de gezellige etentjes 




en het bewonderen van elkaars babyfoto's. Noortje, altijd gezellig om even bij te 
kletsen rond cursussen en besprekingen. Ron, bedankt voor je onmisbare hulp bij 
de online vragenlijsten. Anke, bedankt voor alle uren die je voor mijn project aan de 
telefoon, op de weg en bij patiënten thuis hebt doorgebracht. Ook Bouwe bedankt 
voor je hulp bij het zien van patiënten. Nigara, bedankt voor al je scanwerk. Anne-
Marie, Nadine en Patrick, bedankt voor de uren gezelschap in het vriesveem en de 
hulp bij het uitvullen van vele samples.
Lieve collega's van het voortplantingscentrum, bedankt voor jullie geduld en het 
telkens opvullen van uren wanneer ik afwezig was. Nicole en Evert, bedankt voor de 
eerste zetjes richting het onderzoek. Hjalmar, bedankt voor het telkens aanpassen 
van het rooster als ik weer eens ergens anders heen moest. Pauline, Elisabeth, Berthe, 
Marit, Margriet, Karien, Evelien, Charine, Nina, Christy en Kelly, allemaal heel erg 
bedankt voor alle uren die jullie voor mij extra gedraaid hebben als ik weer eens aan 
mijn onderzoek of in de collegezaal zat. Ramon en Sofi e, ook jullie bedankt voor de 
steun en interesse in de afgelopen jaren. Yvonne en Wendy, bedankt voor jullie hulp 
wanneer ik als beginner even niet meer wist wat er te doen stond. Sharon, bedankt 
voor je hulp met de AMH-database. Hester, Geranne, Cindy, Anne-Lotte, Rivka en Eva, 
bedankt voor de gezelligheid tijdens mijn uurtjes op de 15e. 
Bedankt aan alle vrienden, zowel verder weg als dichtbij. Peter, Ellen, Eric en Helen, 
bedankt voor alle gezellige bordspelmiddagen en -avonden voor de broodnodige 
ontspanning. Bianca, wat was het elke keer genieten met jou en je meisje in het 
Brabantse land. Hopelijk kunnen we dit binnenkort in Spanje weer eens herhalen! 
Hilde, zijn we dan nu allebei eindelijk klaar met alle scripties, artikelen en boeken? 
Het wordt weer hoog tijd voor een musical!
Lieve Lori, wie had dat gedacht toen we in een vertraagde trein aan de praat raakten. 
Al ruim 15 jaar delen we lief en leed met elkaar. Ik had er geen minuut van willen 
missen. Het is dan ook alleen maar logisch dat jij vandaag naast me staat.
Lieve Hans en Helen, bedankt voor jullie steun, interesse en alle uren die jullie met 
de jongens doorbrachten als ik weer eens een examen of overleg had. Mary-ann en 
Roderick, bedankt voor elke keer weer jullie gezelligheid en humor!  
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Lieve pap en mam, bedankt voor het warme nest van waaruit ik heb mogen uitvliegen. 
Nog altijd is het heerlijk thuiskomen in de polder. Bedankt voor de onvoorwaardelijke 
steun en alle hulp die we telkens weer van jullie ontvangen. Lieve opa en Marija, 
bedankt voor alle steun en lieve kaartjes en berichtjes in de afgelopen jaren. Lieve Bas 
en Márcia, bij jullie in Zweden en Engeland kon ik altijd even heerlijk opladen, weg 
van alles. En wat fijn om jullie nu weer dichterbij te hebben. Lieve Marylon en Duncan, 
met jullie is het altijd gezellig. En Lon, wat fijn om ook jou aan mijn zijde te hebben 
vandaag! Lieve Annieck en Martin, jullie dienen als levend voorbeeld om vooral te 
doen waar je jezelf goed bij voelt. Annieck, de voorkant van dit boekje is te danken 
aan jouw creativiteit, dankjewel!
 
Lieve Sjel, wat hebben we onszelf op de hals gehaald door beiden een promotie-
traject in te stappen, dit te combineren met het werk in de kliniek en de zorg voor 
onze jongens. Maar we hebben het gered. Het einde is in zicht! Bedankt dat je er altijd 
voor me bent! 
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